

Dimitri P Mikhailidis

List of Publications by Year in descending order

Source: [//exaly.com/author-pdf/6972626/publications.pdf](https://exaly.com/author-pdf/6972626/publications.pdf)

Version: 2024-02-01

863
papers

33,915
citations

4010

85
h-index

9385

137
g-index

941
all docs

941
docs citations

941
times ranked

29887
citing authors

#	ARTICLE	IF	CITATIONS
1	Mean Platelet Volume: A Link Between Thrombosis and Inflammation?. <i>Current Pharmaceutical Design</i> , 2011, 17, 47-58.	1.9	1,017
2	The role of vascular biomarkers for primary and secondary prevention. A position paper from the European Society of Cardiology Working Group on peripheral circulation. <i>Atherosclerosis</i> , 2015, 241, 507-532.	0.9	613
3	Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis. <i>Lancet, The</i> , 2010, 376, 1916-1922.	12.2	612
4	The Pathogenetic Role of Cortisol in the Metabolic Syndrome: A Hypothesis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 2692-2701.	3.7	527
5	Non-alcoholic fatty liver disease and dyslipidemia: An update. <i>Metabolism: Clinical and Experimental</i> , 2016, 65, 1109-1123.	3.7	397
6	Position paper Statin intolerance – an attempt at a unified definition. Position paper from an International Lipid Expert Panel. <i>Archives of Medical Science</i> , 2015, 1, 1-23.	0.9	318
7	Lifestyle recommendations for the prevention and management of metabolic syndrome: an international panel recommendation. <i>Nutrition Reviews</i> , 2017, 75, 307-326.	6.0	313
8	Orlistat-Associated Adverse Effects and Drug Interactions. <i>Drug Safety</i> , 2008, 31, 53-65.	3.3	306
9	The Relation Between Atherosclerosis and the Neutrophil-Lymphocyte Ratio. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2016, 22, 405-411.	1.7	289
10	Assessment and Clinical Relevance of Non-Fasting and Postprandial Triglycerides: An Expert Panel Statement. <i>Current Vascular Pharmacology</i> , 2011, 9, 258-270.	1.5	270
11	Platelets as Predictors of Vascular Risk: Is There a Practical Index of Platelet Activity?. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2003, 9, 177-190.	1.7	254
12	Lipid-lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel. <i>Nutrition Reviews</i> , 2017, 75, 731-767.	6.0	246
13	Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study. <i>Current Medical Research and Opinion</i> , 2006, 22, 873-883.	2.0	238
14	Elevated serum uric acid levels in metabolic syndrome: an active component or an innocent bystander?. <i>Metabolism: Clinical and Experimental</i> , 2006, 55, 1293-1301.	3.7	236
15	Effect of statins versus untreated dyslipidemia on serum uric acid levels in patients with coronary heart disease: a subgroup analysis of the greek atorvastatin and coronary-heart-disease evaluation (GREACE) study. <i>American Journal of Kidney Diseases</i> , 2004, 43, 589-599.	2.0	226
16	Incidence and predictors of delirium after cardiac surgery: Results from The IPDACS Study. <i>Journal of Psychosomatic Research</i> , 2010, 69, 179-185.	2.9	224
17	Effects of Quercetin on Blood Pressure: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>Journal of the American Heart Association</i> , 2016, 5, .	3.9	221
18	The Role of Nutraceuticals in Statin-Intolerant Patients. <i>Journal of the American College of Cardiology</i> , 2018, 72, 96-118.	5.6	221

#	ARTICLE	IF	CITATIONS
19	Leptin, cardiovascular diseases and type 2 diabetes mellitus. <i>Acta Pharmacologica Sinica</i> , 2018, 39, 1176-1188.	6.2	217
20	The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement. <i>Metabolism: Clinical and Experimental</i> , 2017, 71, 17-32.	3.7	216
21	Elevated heart rate and atherosclerosis: An overview of the pathogenetic mechanisms. <i>International Journal of Cardiology</i> , 2008, 126, 302-312.	1.7	214
22	Lipid lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel. <i>Archives of Medical Science</i> , 2017, 5, 965-1005.	0.9	213
23	Prevalence of statin intolerance: a meta-analysis. <i>European Heart Journal</i> , 2022, 43, 3213-3223.	2.4	206
24	“European Panel on Low Density Lipoprotein (LDL) Subclasses”: A Statement on the Pathophysiology, Atherogenicity and Clinical Significance of LDL Subclasses. <i>Current Vascular Pharmacology</i> , 2011, 9, 533-571.	1.5	190
25	Dysfunctional HDL: A novel important diagnostic and therapeutic target in cardiovascular disease?. <i>Progress in Lipid Research</i> , 2012, 51, 314-324.	12.2	190
26	The Prevalence of Metabolic Syndrome in Various Populations. <i>American Journal of the Medical Sciences</i> , 2007, 333, 362-371.	1.1	188
27	Multiple actions of high-density lipoprotein. <i>Current Opinion in Cardiology</i> , 2008, 23, 370-378.	1.9	182
28	Impact of statin therapy on coronary plaque composition: a systematic review and meta-analysis of virtual histology intravascular ultrasound studies. <i>BMC Medicine</i> , 2015, 13, 229.	5.7	177
29	Effects of Coenzyme Q10 on Statin-Induced Myopathy. <i>Mayo Clinic Proceedings</i> , 2015, 90, 24-34.	2.9	175
30	The effect of smoking on arterial stiffness. <i>Hypertension Research</i> , 2010, 33, 398-410.	2.9	171
31	The role of Toll-like receptors in renal diseases. <i>Nature Reviews Nephrology</i> , 2010, 6, 224-235.	9.7	169
32	The prevalence of the metabolic syndrome using the National Cholesterol Educational Program and International Diabetes Federation definitions. <i>Current Medical Research and Opinion</i> , 2005, 21, 1157-1159.	2.0	167
33	Endocan: A novel inflammatory indicator in cardiovascular disease?. <i>Atherosclerosis</i> , 2015, 243, 339-343.	0.9	166
34	Lipid-modifying effects of nutraceuticals: An evidence-based approach. <i>Nutrition</i> , 2016, 32, 1179-1192.	2.6	162
35	Effect of statin treatment on renal function and serum uric acid levels and their relation to vascular events in patients with coronary heart disease and metabolic syndrome: A subgroup analysis of the GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) Study. <i>Nephrology Dialysis Transplantation</i> , 2006, 22, 118-127.	0.8	160
36	Early vascular benefits of statin therapy. <i>Current Medical Research and Opinion</i> , 2003, 19, 540-556.	2.0	159

#	ARTICLE	IF	CITATIONS
37	Analysis of vitamin D levels in patients with and without statin-associated myalgia – A systematic review and meta-analysis of 7 studies with 2420 patients. <i>International Journal of Cardiology</i> , 2015, 178, 111-116.	1.7	157
38	Statin therapy and plasma coenzyme Q10 concentrations – A systematic review and meta-analysis of placebo-controlled trials. <i>Pharmacological Research</i> , 2015, 99, 329-336.	7.3	154
39	Statin therapy reduces plasma endothelin-1 concentrations: A meta-analysis of 15 randomized controlled trials. <i>Atherosclerosis</i> , 2015, 241, 433-442.	0.9	149
40	Impact of statin therapy on plasma adiponectin concentrations: A systematic review and meta-analysis of 43 randomized controlled trial arms. <i>Atherosclerosis</i> , 2016, 253, 194-208.	0.9	149
41	A review of the carotid and femoral intima-media thickness as an indicator of the presence of peripheral vascular disease and cardiovascular risk factors. <i>Cardiovascular Research</i> , 2002, 54, 528-538.	3.8	148
42	A systematic review and meta-analysis of the effect of statins on plasma asymmetric dimethylarginine concentrations. <i>Scientific Reports</i> , 2015, 5, 9902.	3.5	146
43	Lack of efficacy of resveratrol on C-reactive protein and selected cardiovascular risk factors – Results from a systematic review and meta-analysis of randomized controlled trials. <i>International Journal of Cardiology</i> , 2015, 189, 47-55.	1.7	146
44	The impact of statin therapy on plasma levels of von Willebrand factor antigen. <i>Thrombosis and Haemostasis</i> , 2016, 115, 520-532.	3.5	146
45	Pleiotropic Effects of Statins - Clinical Evidence. <i>Current Pharmaceutical Design</i> , 2009, 15, 479-489.	1.9	145
46	Arterial Stiffness in the Heart Disease of CKD. <i>Journal of the American Society of Nephrology: JASN</i> , 2019, 30, 918-928.	0.5	142
47	Endocan – A Novel Inflammatory Indicator in Newly Diagnosed Patients With Hypertension. <i>Angiology</i> , 2014, 65, 773-777.	1.8	138
48	Platelet function in rheumatoid arthritis: arthritic and cardiovascular implications. <i>Rheumatology International</i> , 2011, 31, 153-164.	3.2	137
49	Adiponectin, lipids and atherosclerosis. <i>Current Opinion in Lipidology</i> , 2017, 28, 347-354.	2.8	136
50	Association of Drinking Pattern and Alcohol Beverage Type With the Prevalence of Metabolic Syndrome, Diabetes, Coronary Heart Disease, Stroke, and Peripheral Arterial Disease in a Mediterranean Cohort. <i>Angiology</i> , 2007, 58, 689-697.	1.8	134
51	Association between statin use and plasma D-dimer levels. <i>Thrombosis and Haemostasis</i> , 2015, 114, 546-557.	3.5	134
52	Drug-induced fibrotic valvular heart disease. <i>Lancet, The</i> , 2009, 374, 577-585.	12.2	132
53	Regulation of Inducible Nitric Oxide Synthase (iNOS) and its Potential Role in Insulin Resistance, Diabetes and Heart Failure. <i>Open Cardiovascular Medicine Journal</i> , 2011, 5, 153-163.	0.4	129
54	Non-alcoholic fatty liver disease, insulin resistance, metabolic syndrome and their association with vascular risk. <i>Metabolism: Clinical and Experimental</i> , 2021, 119, 154770.	3.7	127

#	ARTICLE	IF	CITATIONS
55	Serum ferritin is a discriminant marker for both fibrosis and inflammation in histologically proven non-alcoholic fatty liver disease patients. <i>Liver International</i> , 2011, 31, 730-739.	4.0	126
56	Lipoprotein Subfractions in Metabolic Syndrome and Obesity: Clinical Significance and Therapeutic Approaches. <i>Nutrients</i> , 2013, 5, 928-948.	4.2	126
57	Influence of Smoking on Predictors of Vascular Disease. <i>Angiology</i> , 2003, 54, 507-530.	1.8	124
58	Ghrelin Can Bind to a Species of High Density Lipoprotein Associated with Paraoxonase. <i>Journal of Biological Chemistry</i> , 2003, 278, 8877-8880.	3.5	124
59	Serum endocan levels as a marker of disease activity in patients with Behçet disease. <i>Journal of the American Academy of Dermatology</i> , 2014, 70, 291-296.	1.3	121
60	Cyclosporine A enhances platelet aggregation. <i>Kidney International</i> , 1987, 32, 889-895.	5.6	120
61	Serum Uric Acid as an Independent Predictor of Early Death After Acute Stroke. <i>Circulation Journal</i> , 2007, 71, 1120-1127.	1.7	120
62	Clinical Relevance of Postprandial Lipaemia. <i>Current Medicinal Chemistry</i> , 2005, 12, 1931-1945.	2.5	116
63	Spirolactone versus eplerenone for the treatment of idiopathic hyperaldosteronism. <i>Expert Opinion on Pharmacotherapy</i> , 2008, 9, 509-515.	1.9	116
64	Cilostazol for intermittent claudication. <i>The Cochrane Library</i> , 2014, , CD003748.	2.9	115
65	Lipid accumulation product and triglycerides/glucose index are useful predictors of insulin resistance. <i>Journal of Diabetes and Its Complications</i> , 2018, 32, 266-270.	2.5	115
66	Pheochromocytoma: an update on genetics and management. <i>Endocrine-Related Cancer</i> , 2007, 14, 935-956.	3.4	114
67	Components of the Metabolic Syndrome and Risk for First-Ever Acute Ischemic Nonembolic Stroke in Elderly Subjects. <i>Stroke</i> , 2005, 36, 1372-1376.	5.0	112
68	Lower carbohydrate diets and all-cause and cause-specific mortality: a population-based cohort study and pooling of prospective studies. <i>European Heart Journal</i> , 2019, 40, 2870-2879.	2.4	112
69	European Panel On Low Density Lipoprotein (LDL) Subclasses: A Statement on the Pathophysiology, Atherogenicity and Clinical Significance of LDL Subclasses: Executive Summary. <i>Current Vascular Pharmacology</i> , 2011, 9, 531-532.	1.5	110
70	The Role of Fibrate Treatment in Dyslipidemia: An Overview. <i>Current Pharmaceutical Design</i> , 2013, 19, 3124-3131.	1.9	108
71	Marital Status, Cardiovascular Diseases, and Cardiovascular Risk Factors: A Review of the Evidence. <i>Journal of Women's Health</i> , 2017, 26, 624-632.	3.4	106
72	Diagnostic Value of Postprandial Triglyceride Testing in Healthy Subjects: A Meta-Analysis. <i>Current Vascular Pharmacology</i> , 2011, 9, 271-280.	1.5	105

#	ARTICLE	IF	CITATIONS
73	The hypertriglyceridemic waist phenotype is a predictor of elevated levels of small, dense LDL cholesterol. <i>Lipids</i> , 2006, 41, 647-654.	1.7	104
74	Effect of ezetimibe monotherapy on the concentration of lipoprotein subfractions in patients with primary dyslipidaemia. <i>Current Medical Research and Opinion</i> , 2007, 23, 1169-1176.	2.0	104
75	Should Adipokines be Considered in the Choice of the Treatment of Obesity-Related Health Problems?. <i>Current Drug Targets</i> , 2010, 11, 122-135.	2.3	100
76	Statins and Renal Function. <i>Angiology</i> , 2002, 53, 493-502.	1.8	95
77	Comparison of four definitions of the metabolic syndrome in a Greek (Mediterranean) population. <i>Current Medical Research and Opinion</i> , 2010, 26, 713-719.	2.0	93
78	Clinical importance and therapeutic modulation of small dense low-density lipoprotein particles. <i>Expert Opinion on Biological Therapy</i> , 2007, 7, 53-72.	3.2	92
79	Statins decrease all-cause mortality only in CKD patients not requiring dialysis therapyâ€”A meta-analysis of 11 randomized controlled trials involving 21,295 participants. <i>Pharmacological Research</i> , 2013, 72, 35-44.	7.3	92
80	Is Nonalcoholic Fatty Liver Disease Indeed the Hepatic Manifestation of Metabolic Syndrome?. <i>Current Vascular Pharmacology</i> , 2018, 16, 219-227.	1.5	92
81	The Rationale for Comparative Studies of Accelerated Atherosclerosis in Rheumatic Diseases. <i>Current Vascular Pharmacology</i> , 2010, 8, 437-449.	1.5	91
82	Dietary inflammatory index and cardiometabolic risk in US adults. <i>Atherosclerosis</i> , 2018, 276, 23-27.	0.9	91
83	Evaluation of the effect of oxidative stress and vitamin E supplementation on renal function in rats with streptozotocin-induced Type 1 diabetes. <i>Journal of Diabetes and Its Complications</i> , 2009, 23, 130-136.	2.5	89
84	Introducing the â€œDruceboâ€™ effect in statin therapy: a systematic review of studies comparing reported rates of statinâ€”associated muscle symptoms, under blinded and openâ€”label conditions. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2018, 9, 1023-1033.	7.5	89
85	11beta-Hydroxysteroid dehydrogenase type 1 inhibitors: novel agents for the treatment of metabolic syndrome and obesity-related disorders?. <i>Metabolism: Clinical and Experimental</i> , 2013, 62, 21-33.	3.7	88
86	The impact of type of dietary protein, animal versus vegetable, in modifying cardiometabolic risk factors: A position paper from the International Lipid Expert Panel (ILEP). <i>Clinical Nutrition</i> , 2021, 40, 255-276.	5.2	88
87	Uric Acid and Diabetes: Is there a Link?. <i>Current Pharmaceutical Design</i> , 2013, 19, 4930-4937.	1.9	88
88	Emerging Indications for Statins: A Pluripotent Family of Agents with Several Potential Applications. <i>Current Pharmaceutical Design</i> , 2007, 13, 3622-3636.	1.9	87
89	Acute pancreatitis in pregnancy: an overview. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2011, 159, 261-266.	1.1	87
90	The Use of Citrated Whole Blood in Thromboelastography. <i>Anesthesia and Analgesia</i> , 2000, 90, 1086-1088.	2.5	85

#	ARTICLE	IF	CITATIONS
91	The mechanisms of atrial fibrillation in hyperthyroidism. <i>Thyroid Research</i> , 2009, 2, 4.	1.7	85
92	Prevalence of atherosclerotic vascular disease among subjects with the metabolic syndrome with or without diabetes mellitus: the METS-GREECE Multicentre Study. <i>Current Medical Research and Opinion</i> , 2004, 20, 1691-1701.	2.0	84
93	Effect of ezetimibe in patients who cannot tolerate statins or cannot get to the low density lipoprotein cholesterol target despite taking a statin. <i>Current Medical Research and Opinion</i> , 2007, 23, 2183-2192.	2.0	83
94	Influence of platelet count and activity on thromboelastography parameters. <i>Platelets</i> , 2003, 14, 219-224.	2.1	81
95	The Effect of Short-Term Treatment with Simvastatin on Renal Function in Patients with Peripheral Arterial Disease. <i>Angiology</i> , 2004, 55, 53-62.	1.8	81
96	Statins: An essential component in the management of carotid artery disease. <i>Journal of Vascular Surgery</i> , 2007, 46, 373-386.e9.	1.1	81
97	Do we need to consider inflammatory markers when we treat atherosclerotic disease?. <i>Atherosclerosis</i> , 2008, 200, 1-12.	0.9	80
98	Takotsubo cardiomyopathy – The current state of knowledge. <i>International Journal of Cardiology</i> , 2010, 142, 120-125.	1.7	79
99	Effect of tobacco smoking and smoking cessation on plasma lipoproteins and associated major cardiovascular risk factors: a narrative review. <i>Current Medical Research and Opinion</i> , 2013, 29, 1263-1274.	2.0	79
100	Comparative efficacy of the addition of ezetimibe to statin vs statin titration in patients with hypercholesterolaemia: systematic review and meta-analysis. <i>Current Medical Research and Opinion</i> , 2011, 27, 1191-1210.	2.0	78
101	Metabolic syndrome and renal disease. <i>International Journal of Cardiology</i> , 2013, 164, 141-150.	1.7	76
102	Low serum albumin: A neglected predictor in patients with cardiovascular disease. <i>European Journal of Internal Medicine</i> , 2022, 102, 24-39.	2.3	76
103	The Role of Serotonin (5-Hydroxytryptamine 1A and 1B) Receptors in Prostate Cancer Cell Proliferation. <i>Journal of Urology</i> , 2006, 176, 1648-1653.	3.9	75
104	Safety and impact on cardiovascular events of long-term multifactorial treatment in patients with metabolic syndrome and abnormal liver function tests: a post hoc analysis of the randomised ATTEMPT study. <i>Archives of Medical Science</i> , 2011, 5, 796-805.	0.9	74
105	Effects of newer antidiabetic drugs on nonalcoholic fatty liver and steatohepatitis: Think out of the box!. <i>Metabolism: Clinical and Experimental</i> , 2019, 101, 154001.	3.7	74
106	Lipid-lowering therapy and renin-angiotensin-aldosterone system inhibitors in the era of the COVID-19 pandemic. <i>Archives of Medical Science</i> , 2020, 16, 485-489.	0.9	74
107	Apolipoprotein E Knockout Models. <i>Current Pharmaceutical Design</i> , 2008, 14, 338-351.	1.9	73
108	Dyslipidemia as a Risk Factor for Ischemic Stroke. <i>Current Topics in Medicinal Chemistry</i> , 2009, 9, 1291-1297.	2.0	73

#	ARTICLE	IF	CITATIONS
109	A cross-sectional study of the effects of hormon replacement therapy on the cardiovascular disease risk profile in healthy postmenopausal women. <i>Fertility and Sterility</i> , 2002, 77, 945-951.	1.0	72
110	Effect of Ezetimibe Monotherapy on Plasma Lipoprotein(a) Concentrations in Patients with Primary Hypercholesterolemia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>Drugs</i> , 2018, 78, 453-462.	11.2	72
111	The effect of serotonin and serotonin antagonists on bladder cancer cell proliferation. <i>BJU International</i> , 2006, 97, 634-639.	2.8	71
112	Epicardial fat and vascular risk. <i>Current Opinion in Cardiology</i> , 2013, 28, 458-463.	1.9	71
113	The effects of antiepileptic drugs on vascular risk factors: A narrative review. <i>Seizure: the Journal of the British Epilepsy Association</i> , 2014, 23, 677-684.	2.0	71
114	Effect of nonesterified fatty acids on the stability of prostacyclin activity. <i>Metabolism: Clinical and Experimental</i> , 1983, 32, 717-721.	3.7	70
115	The effect of clopidogrel, aspirin and both antiplatelet drugs on platelet function in patients with peripheral arterial disease. <i>Platelets</i> , 2004, 15, 117-125.	2.1	70
116	Effect of atorvastatin on highdensity lipoprotein cholesteroland its relationship withcoronary events: a subgroupanalysis of the GREekAtorvastatin and Coronary-heart-disease Evaluation (GREACE) Study. <i>Current Medical Research and Opinion</i> , 2004, 20, 627-637.	2.0	69
117	Angiotensin II reactivation and aldosterone escape phenomena in reninâ€“angiotensinâ€“aldosterone system blockade: is oral renin inhibition the solution?. <i>Expert Opinion on Pharmacotherapy</i> , 2007, 8, 529-535.	1.9	69
118	Effectiveness of Ezetimibe Alone or in Combination With Twice a Week Atorvastatin (10 mg) for Statin Intolerant High-Risk Patients. <i>American Journal of Cardiology</i> , 2008, 101, 483-485.	1.6	69
119	A meta-analysis of the role of statins on renal outcomes in patients with chronic kidney disease. Is the duration of therapy important?. <i>International Journal of Cardiology</i> , 2013, 168, 5437-5447.	1.7	69
120	Is statin-modified reduction in lipids the most important preventive therapy for cardiovascular disease? A pro/con debate. <i>BMC Medicine</i> , 2016, 14, 4.	5.7	69
121	Adrenal incidentaloma: a diagnostic challenge. <i>Hormones</i> , 2009, 8, 163-184.	2.1	68
122	Statins and renal function in patients with diabetes mellitus. <i>Current Medical Research and Opinion</i> , 2003, 19, 615-617.	2.0	67
123	Targeting vascular risk in patients with metabolic syndrome but without diabetes. <i>Metabolism: Clinical and Experimental</i> , 2005, 54, 1065-1074.	3.7	67
124	Hyperuricaemia. <i>Journal of Cardiovascular Medicine</i> , 2013, 14, 397-402.	1.5	67
125	Endocan Levels and Subclinical Atherosclerosis in Patients With Systemic Lupus Erythematosus. <i>Angiology</i> , 2016, 67, 749-755.	1.8	67
126	Treating to target patients with primary hyperlipidaemia:comparison of the effects of ATOrvastatin and ROSuvastatin (the ATOROS study). <i>Current Medical Research and Opinion</i> , 2006, 22, 1123-1131.	2.0	66

#	ARTICLE	IF	CITATIONS
127	Visfatin/PBEF and Atherosclerosis-Related Diseases. <i>Current Vascular Pharmacology</i> , 2010, 8, 12-28.	1.5	66
128	Effects of selected dietary constituents on high-sensitivity C-reactive protein levels in U.S. adults. <i>Annals of Medicine</i> , 2018, 50, 1-6.	3.9	66
129	Compliance with lipid-lowering therapy and its impact on cardiovascular morbidity and mortality. <i>Expert Opinion on Drug Safety</i> , 2008, 7, 717-725.	2.5	64
130	Nonalcoholic Fatty Liver Disease and Cardiovascular Disease: a Review of Shared Cardiometabolic Risk Factors. <i>Hypertension</i> , 2022, 79, 1319-1326.	5.0	64
131	Adrenergic modulation of vascular prostacyclin (PGI ₂) secretion. <i>European Journal of Pharmacology</i> , 1985, 114, 33-40.	3.6	63
132	Does Diabetes Mellitus Play a Role in Restenosis and Patency Rates Following Lower Extremity Peripheral Arterial Revascularization? A Critical Overview. <i>Annals of Vascular Surgery</i> , 2008, 22, 481-491.	1.0	63
133	Definition of Best Medical Treatment in Asymptomatic and Symptomatic Carotid Artery Stenosis. <i>Angiology</i> , 2016, 67, 411-419.	1.8	63
134	Does vitamin D supplementation alter plasma adipokines concentrations? A systematic review and meta-analysis of randomized controlled trials. <i>Pharmacological Research</i> , 2016, 107, 360-371.	7.3	62
135	Lipid-lowering activity of artichoke extracts: A systematic review and meta-analysis. <i>Critical Reviews in Food Science and Nutrition</i> , 2018, 58, 2549-2556.	10.1	62
136	Fenofibrate: Metabolic and Pleiotropic Effects. <i>Current Vascular Pharmacology</i> , 2005, 3, 87-98.	1.5	61
137	The link between insulin resistance parameters and serum uric acid is mediated by adiposity. <i>Atherosclerosis</i> , 2018, 270, 180-186.	0.9	61
138	Effect of Fenofibrate on Serum Inflammatory Markers in Patients With High Triglyceride Values. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2004, 9, 27-33.	2.2	60
139	Head-to-head comparison of statins versus fibrates in reducing plasma fibrinogen concentrations: A systematic review and meta-analysis. <i>Pharmacological Research</i> , 2016, 103, 236-252.	7.3	60
140	The meaning of hypokalemia in heart failure. <i>International Journal of Cardiology</i> , 2012, 158, 12-17.	1.7	59
141	The effect of sildenafil on corpus cavernosal smooth muscle relaxation and cyclic GMP formation in the diabetic rabbit. <i>European Journal of Pharmacology</i> , 2001, 425, 57-64.	3.6	58
142	Value of Thromboelastography in the Assessment of Platelet Function. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2003, 9, 137-142.	1.7	58
143	The role of fibrinogen and fibrinolysis in peripheral arterial disease. <i>Thrombosis Research</i> , 2008, 122, 1-12.	1.7	58
144	HDL-cholesterol and the Treatment of Coronary Heart Disease: Contrasting Effects of Atorvastatin and Simvastatin. <i>Current Medical Research and Opinion</i> , 2000, 16, 139-146.	2.0	57

#	ARTICLE	IF	CITATIONS
145	Optical Techniques in the Assessment of Peripheral Arterial Disease. <i>Current Vascular Pharmacology</i> , 2007, 5, 53-59.	1.5	56
146	Coagulation, Platelets, and Acute Pancreatitis. <i>Pancreas</i> , 2007, 34, 15-20.	1.1	56
147	Obesity and Arterial Compliance Alterations. <i>Current Vascular Pharmacology</i> , 2010, 8, 155-168.	1.5	56
148	Impact of L-carnitine on plasma lipoprotein(a) concentrations: A systematic review and meta-analysis of randomized controlled trials. <i>Scientific Reports</i> , 2016, 6, 19188.	3.5	56
149	Statin + fibrate combination therapy. <i>International Journal of Cardiology</i> , 1999, 69, 237-244.	1.7	55
150	Dyslipidaemia of Obesity, Metabolic Syndrome and Type 2 Diabetes Mellitus: the Case for Residual Risk Reduction After Statin Treatment. <i>Open Cardiovascular Medicine Journal</i> , 2011, 5, 24-34.	0.4	55
151	Association of types of dietary fats and all-cause and cause-specific mortality: A prospective cohort study and meta-analysis of prospective studies with 1,164,029 participants. <i>Clinical Nutrition</i> , 2020, 39, 3677-3686.	5.2	55
152	Serum Uric Acid and Diabetes: From Pathophysiology to Cardiovascular Disease. <i>Current Pharmaceutical Design</i> , 2021, 27, 1941-1951.	1.9	55
153	Reaching goal in hypercholesterolaemia: dual inhibition of cholesterol synthesis and absorption with simvastatin plus ezetimibe. <i>Current Medical Research and Opinion</i> , 2006, 22, 511-528.	2.0	54
154	Purinergic receptor-mediated effects of ATP in high-grade bladder cancer. <i>BJU International</i> , 2008, 101, 106-112.	2.8	54
155	ASAS40 and ASDAS clinical responses in the ABILITY-1 clinical trial translate to meaningful improvements in physical function, health-related quality of life and work productivity in patients with non-radiographic axial spondyloarthritis. <i>Rheumatology</i> , 2016, 55, 80-88.	2.1	54
156	Peripheral Arterial Disease: A Missed Opportunity to Administer Statins so as to Reduce Cardiac Morbidity and Mortality. <i>Current Medicinal Chemistry</i> , 2005, 12, 443-452.	2.5	53
157	Hyperuricaemia and Non-Alcoholic Fatty Liver Disease (NAFLD): A Relationship with Implications for Vascular Risk?. <i>Current Vascular Pharmacology</i> , 2011, 9, 698-705.	1.5	53
158	Thromboxane A2 analogue (U-46619) stimulates vascular PGI2 synthesis. <i>European Journal of Pharmacology</i> , 1985, 107, 259-262.	3.6	52
159	Smoking Diminishes the Beneficial Effect of Statins: Observations from the Landmark Trials. <i>Angiology</i> , 2001, 52, 575-587.	1.8	52
160	Statins and Peripheral Arterial Disease: Potential Mechanisms and Clinical Benefits. <i>Annals of Vascular Surgery</i> , 2006, 20, 696-705.	1.0	52
161	Lipoprotein a: where are we now?. <i>Current Opinion in Cardiology</i> , 2009, 24, 351-357.	1.9	52
162	An update on biomarkers of heart failure in hypertensive patients. <i>Journal of Hypertension</i> , 2012, 30, 1681-1689.	0.5	52

#	ARTICLE	IF	CITATIONS
163	PCSK9 Inhibition - A Novel Mechanism to Treat Lipid Disorders?. Current Pharmaceutical Design, 2013, 19, 3869-3877.	1.9	52
164	Lone atrial fibrillation: what do we know?. Heart, 2010, 96, 498-503.	3.9	51
165	Role of Antihypertensive Drugs in Arterial "De-Stiffening"™ and Central Pulsatile Hemodynamics. American Journal of Cardiovascular Drugs, 2012, 12, 143-156.	2.4	51
166	Abnormal Peri-Organ or Intra-organ Fat (APIFat) Deposition: An Underestimated Predictor of Vascular Risk?. Current Vascular Pharmacology, 2016, 14, 432-441.	1.5	51
167	Iron chelators inhibit human platelet aggregation, thromboxane A ₂ synthesis and lipoxigenase activity. FEBS Letters, 1989, 245, 105-109.	2.8	50
168	Effect of Ciprofibrate on C-Reactive Protein and Fibrinogen Levels. Angiology, 2002, 53, 273-277.	1.8	50
169	Both the ADP receptors P2Y 1 and P2Y 12 , play a role in controlling shape change in human platelets. Platelets, 2003, 14, 15-20.	2.1	50
170	Effect of extracellular ATP on the growth of hormone-refractory prostate cancer in vivo. BJU International, 2008, 102, 108-112.	2.8	50
171	Liver Enzymes: Potential Cardiovascular Risk Markers?. Current Pharmaceutical Design, 2011, 17, 3632-3643.	1.9	50
172	Comparison of the five 2011 guidelines for the treatment of carotid stenosis. Journal of Vascular Surgery, 2012, 55, 1504-1508.	1.1	50
173	Consumption of dairy product and its association with total and cause-specific mortality " A population-based cohort study and meta-analysis. Clinical Nutrition, 2019, 38, 2833-2845.	5.2	50
174	Homocysteine and diabetes: Role in macrovascular and microvascular complications. Journal of Diabetes and Its Complications, 2021, 35, 107834.	2.5	50
175	Cigarette smoking and erectile dysfunction. Perspectives in Public Health, 1998, 118, 151-155.	0.5	49
176	Upper gastrointestinal haemorrhage complicating antiplatelet treatment with aspirin and/or clopidogrel: Where we are now?. Platelets, 2006, 17, 1-6.	2.1	49
177	Internal Carotid Artery Occlusion: Association With Atherosclerotic Disease in Other Arterial Beds and Vascular Risk Factors. Angiology, 2007, 58, 329-335.	1.8	49
178	Postoperative Atrial Fibrillation - What Do We Really Know?. Current Vascular Pharmacology, 2010, 8, 553-572.	1.5	49
179	Review Article: Effects of Plant Sterols and Stanols Beyond Low-Density Lipoprotein Cholesterol Lowering. Journal of Cardiovascular Pharmacology and Therapeutics, 2010, 15, 120-134.	2.2	49
180	Mechanisms to explain the poor results of carotid artery stenting (CAS) in symptomatic patients to date and options to improve CAS outcomes. Journal of Vascular Surgery, 2010, 52, 1367-1375.	1.1	49

#	ARTICLE	IF	CITATIONS
181	Non-alcoholic fatty liver disease and steatohepatitis: State of the art on effective therapeutics based on the gold standard method for diagnosis. <i>Molecular Metabolism</i> , 2021, 50, 101049.	6.7	49
182	Characteristics Other than the Diagnostic Criteria Associated with Metabolic Syndrome: An Overview. <i>Current Vascular Pharmacology</i> , 2014, 12, 627-641.	1.5	49
183	Near-Infrared Spectroscopy Assessment Following Exercise Training in Patients With Intermittent Claudication and in Untrained Healthy Participants. <i>Vascular and Endovascular Surgery</i> , 2012, 46, 315-324.	0.7	48
184	Editorial: Ageing, Longevity, Exceptional Longevity and Related Genetic and Non Genetics Markers: Panel Statement. <i>Current Vascular Pharmacology</i> , 2014, 12, 659-661.	1.5	48
185	Should we expand the concept of coronary heart disease equivalents?. <i>Current Opinion in Cardiology</i> , 2014, 29, 389-395.	1.9	48
186	Obesity, Metabolic Syndrome and the Risk of Microvascular Complications in Patients with Diabetes mellitus. <i>Current Pharmaceutical Design</i> , 2019, 25, 2051-2059.	1.9	48
187	Apolipoprotein E Polymorphism and Atherosclerosis. <i>Angiology</i> , 2003, 54, 59-71.	1.8	47
188	Statins Exert Multiple Beneficial Effects on Patients Undergoing Percutaneous Revascularization Procedures. <i>Current Drug Targets</i> , 2007, 8, 942-951.	2.3	47
189	Association Between Ankle - Brachial Index and Risk Factor Profile in Patients Newly Diagnosed With Intermittent Claudication. <i>Circulation Journal</i> , 2008, 72, 441-448.	1.7	47
190	Association between the changes in renal function and serum uric acid levels during multifactorial intervention and clinical outcome in patients with metabolic syndrome. A post hoc analysis of the ATTEMPT study. <i>Current Medical Research and Opinion</i> , 2011, 27, 1659-1668.	2.0	47
191	Definition of Postprandial Lipaemia. <i>Current Vascular Pharmacology</i> , 2011, 9, 292-301.	1.5	47
192	Signaling mechanisms of a water soluble curcumin derivative in experimental type 1 diabetes with cardiomyopathy. <i>Diabetology and Metabolic Syndrome</i> , 2013, 5, 13.	2.8	47
193	Tibolone decreases Lipoprotein(a) levels in postmenopausal women: A systematic review and meta-analysis of 12 studies with 1009 patients. <i>Atherosclerosis</i> , 2015, 242, 87-96.	0.9	47
194	Doseâ€response effects of atorvastatin and simvastatin on high-density lipoprotein cholesterol in hypercholesterolaemic patients: a review of five comparative studies. <i>International Journal of Cardiology</i> , 2002, 84, 53-57.	1.7	46
195	Characterization of calciumâ€independent purinergic receptorâ€mediated apoptosis in hormoneâ€refractory prostate cancer. <i>BJU International</i> , 2008, 101, 352-359.	2.8	46
196	Vascular risk factors in South Asians. <i>International Journal of Cardiology</i> , 2008, 128, 5-16.	1.7	46
197	The significance of preoperative atrial fibrillation in patients undergoing cardiac surgery: preoperative atrial fibrillationâ€still underestimated opponent. <i>Europace</i> , 2008, 10, 1266-1270.	1.8	46
198	IMproving the imPlemEntation of cuRrent guidelines for the mAnagement of major coronary heart disease risk factors by multifactorial interVEntion. The IMPERATIVE renal analysis. <i>Archives of Medical Science</i> , 2011, 6, 984-992.	0.9	46

#	ARTICLE	IF	CITATIONS
199	Why Calls for More Routine Carotid Stenting Are Currently Inappropriate. <i>Stroke</i> , 2013, 44, 1186-1190.	5.0	46
200	Abdominal aortic aneurysms and diabetes mellitus. <i>Journal of Diabetes and Its Complications</i> , 2015, 29, 1330-1336.	2.5	46
201	Efficacy and Safety of Alternate-Day Versus Daily Dosing of Statins: a Systematic Review and Meta-Analysis. <i>Cardiovascular Drugs and Therapy</i> , 2017, 31, 419-431.	2.9	46
202	Statin discontinuation: an underestimated risk?. <i>Current Medical Research and Opinion</i> , 2008, 24, 3059-3062.	2.0	45
203	Renal Function Impairment in Peripheral Arterial Disease: An Important Parameter that Should not Be Neglected. <i>Annals of Vascular Surgery</i> , 2009, 23, 690-699.	1.0	45
204	Dyslipidaemia, Hypercoagulability and the Metabolic Syndrome. <i>Current Vascular Pharmacology</i> , 2006, 4, 175-183.	1.5	44
205	Assessing The Treatment Effect in Metabolic Syndrome Without Perceptible Diabetes (ATTEMPT): A Prospective-Randomized Study in Middle Aged Men and Women. <i>Current Vascular Pharmacology</i> , 2011, 9, 647-657.	1.5	44
206	Effects of morning vs evening statin administration on lipid profile: A systematic review and meta-analysis. <i>Journal of Clinical Lipidology</i> , 2017, 11, 972-985.e9.	1.6	44
207	Corrosion of copper in pure O ₂ -free water?. <i>Corrosion Science</i> , 2018, 137, 1-12.	6.7	44
208	Metabolic Syndrome and Non-Cardiac Vascular Diseases: An Update from Human Studies. <i>Current Pharmaceutical Design</i> , 2014, 20, 4944-4952.	1.9	44
209	Beyond LDL-C – The Importance of Raising HDL-C. <i>Current Medical Research and Opinion</i> , 2002, 18, 36-44.	2.0	43
210	Oral and ocular/orbital manifestations of temporal arteritis: a disease with deceptive clinical symptoms and devastating consequences. <i>Clinical Rheumatology</i> , 2007, 26, 1044-1048.	2.4	43
211	Ankle-Brachial Index: A Marker of Both Peripheral Arterial Disease and Systemic Atherosclerosis As Well As a Predictor of Vascular Events. <i>Angiology</i> , 2010, 61, 521-523.	1.8	43
212	Statins can improve proteinuria and glomerular filtration rate loss in chronic kidney disease patients, further reducing cardiovascular risk. Fact or fiction?. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 1449-1461.	1.9	43
213	Carotid Bifurcation Geometry and Atherosclerosis. <i>Angiology</i> , 2017, 68, 757-764.	1.8	43
214	Dietary food patterns and glucose/insulin homeostasis: a cross-sectional study involving 24,182 adult Americans. <i>Lipids in Health and Disease</i> , 2017, 16, 192.	3.1	43
215	Ezetimibe Therapy for Dyslipidemia: An Update. <i>Current Pharmaceutical Design</i> , 2013, 19, 3107-3114.	1.9	43
216	Vascular Dysfunction of COVID-19 Is Partially Reverted in the Long-Term. <i>Circulation Research</i> , 2022, 130, 1276-1285.	6.5	43

#	ARTICLE	IF	CITATIONS
217	C-reactive protein (CRP): more than just an innocent bystander?. <i>Current Medical Research and Opinion</i> , 2008, 24, 75-78.	2.0	42
218	Welcome to CMRO's 40th Anniversary Issue. <i>Current Medical Research and Opinion</i> , 2012, 28, 1-1.	2.0	42
219	Sodium-glucose Cotransporter 2 Inhibitors (SGLT2i): Their Role in Cardiometabolic Risk Management. <i>Current Pharmaceutical Design</i> , 2017, 23, 1522-1532.	1.9	42
220	Step-by-step diagnosis and management of the nocebo/drug effect in statin-associated muscle symptoms patients: a position paper from the International Lipid Expert Panel (ILEP). <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2022, 13, 1596-1622.	7.5	42
221	Plasma visfatin and retinol binding protein-4 levels in patients with type 2 diabetes mellitus and their relationship to adiposity and fatty liver. <i>Clinical Biochemistry</i> , 2011, 44, 1457-1463.	2.0	41
222	Sodium-glucose co-transporter-2 inhibitors (SGLT2i) use and risk of amputation: an expert panel overview of the evidence. <i>Metabolism: Clinical and Experimental</i> , 2019, 96, 92-100.	3.7	41
223	Combined Dyslipidemia: Should the Focus be LDL Cholesterol or Atherogenic Dyslipidemia?. <i>Current Pharmaceutical Design</i> , 2013, 19, 3858-3868.	1.9	41
224	Postprandial Hypertriglyceridaemia Revisited in the Era of Non-Fasting Lipid Profile Testing: A 2019 Expert Panel Statement, Main Text. <i>Current Vascular Pharmacology</i> , 2019, 17, 498-514.	1.5	41
225	The effect of nitric oxide and peroxynitrite on rabbit cavernosal smooth muscle relaxation. <i>World Journal of Urology</i> , 2001, 19, 220-224.	2.4	40
226	Risk Modification in Patients with Peripheral Arterial Disease: A Retrospective Survey. <i>Angiology</i> , 2005, 56, 279-287.	1.8	40
227	Definitions of Metabolic Syndrome: Where are We Now?. <i>Current Vascular Pharmacology</i> , 2006, 4, 185-197.	1.5	40
228	The Role of Thiols in Liver Ischemia-Reperfusion Injury. <i>Current Pharmaceutical Design</i> , 2006, 12, 2891-2901.	1.9	40
229	Role and significance of statins in the treatment of hypertensive patients. <i>Current Medical Research and Opinion</i> , 2009, 25, 1995-2005.	2.0	40
230	Statin-based treatment for cardiovascular risk and non-alcoholic fatty liver disease. Killing two birds with one stone?. <i>Annals of Medicine</i> , 2011, 43, 167-171.	3.9	40
231	Nutrition During Pregnancy and the Effect of Carbohydrates on the Offspring's Metabolic Profile: In Search of the "Perfect Maternal Diet". <i>Open Cardiovascular Medicine Journal</i> , 2011, 5, 103-109.	0.4	40
232	Statins and cardiovascular outcomes in elderly and younger patients with coronary artery disease: a post hoc analysis of the GREACE study. <i>Archives of Medical Science</i> , 2013, 3, 418-426.	0.9	40
233	Lipid-modifying effects of krill oil in humans: systematic review and meta-analysis of randomized controlled trials. <i>Nutrition Reviews</i> , 2017, 75, 361-373.	6.0	40
234	The potential role of statins in preeclampsia and dyslipidemia during gestation: a narrative review. <i>Expert Opinion on Investigational Drugs</i> , 2018, 27, 427-435.	4.2	40

#	ARTICLE	IF	CITATIONS
235	Mean platelet volume and coronary artery disease. <i>Current Opinion in Cardiology</i> , 2019, 34, 390-398.	1.9	40
236	Endothelial function, arterial stiffness and lipid lowering drugs. <i>Expert Opinion on Therapeutic Targets</i> , 2007, 11, 1143-1160.	3.4	39
237	Atorvastatin: safety and tolerability. <i>Expert Opinion on Drug Safety</i> , 2010, 9, 667-674.	2.5	39
238	The Role of Statins in the Treatment of Type 2 Diabetes Mellitus: An Update. <i>Current Pharmaceutical Design</i> , 2014, 20, 3665-3674.	1.9	39
239	Hemostatic Factors and the Metabolic Syndrome. <i>Current Vascular Pharmacology</i> , 2014, 11, 880-905.	1.5	39
240	The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study. <i>Current Medical Research and Opinion</i> , 2002, 18, 215-219.	2.0	38
241	Sex-associated effect of CETP and LPL polymorphisms on postprandial lipids in familial hypercholesterolaemia. <i>Lipids in Health and Disease</i> , 2009, 8, 24.	3.1	38
242	The effects of statins on blood pressure in normotensive or hypertensive subjects – A meta-analysis of randomized controlled trials. <i>International Journal of Cardiology</i> , 2013, 168, 2816-2824.	1.7	38
243	The effect of bergamot on dyslipidemia. <i>Phytomedicine</i> , 2016, 23, 1175-1181.	5.4	38
244	Effects of Allopurinol on Endothelial Function: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials. <i>Drugs</i> , 2018, 78, 99-109.	11.2	38
245	Circadian changes in the hemostatic system in healthy men and patients with cardiovascular diseases. <i>Medical Science Monitor</i> , 2009, 15, 203-208.	1.2	38
246	Ethanol Ingestion Inhibits Human Whole Blood Platelet Impedance Aggregation. <i>American Journal of Clinical Pathology</i> , 1987, 88, 342-345.	0.8	37
247	A review of the lipid-related effects of fluvastatin. <i>Current Medical Research and Opinion</i> , 2005, 21, 231-243.	2.0	37
248	The Role of Endocannabinoid System Blockade in the Treatment of the Metabolic Syndrome. <i>Journal of Clinical Pharmacology</i> , 2007, 47, 642-652.	2.1	37
249	Vitamin D and Metabolic Syndrome: Is There a Link?. <i>Current Pharmaceutical Design</i> , 2010, 16, 3417-3434.	1.9	37
250	Dapagliflozin: more than just another oral glucose-lowering agent?. <i>Expert Opinion on Investigational Drugs</i> , 2010, 19, 1581-1589.	4.2	37
251	Effects of statins on lipid profile in chronic kidney disease patients: a meta-analysis of randomized controlled trials. <i>Current Medical Research and Opinion</i> , 2013, 29, 435-451.	2.0	37
252	ETC-1002: A future option for lipid disorders?. <i>Atherosclerosis</i> , 2014, 237, 705-710.	0.9	37

#	ARTICLE	IF	CITATIONS
253	Anti-inflammatory properties of an isoxazole derivative â€” MZO-2. <i>Pharmacological Reports</i> , 2016, 68, 894-902.	3.4	37
254	Effect of omega-3 supplements on plasma apolipoprotein C-III concentrations: a systematic review and meta-analysis of randomized controlled trials. <i>Annals of Medicine</i> , 2018, 50, 565-575.	3.9	37
255	Effect of Ciprofibrate on Lipoproteins, Fibrinogen, Renal Function, and Hepatic Enzymes. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2002, 7, 219-226.	2.2	36
256	The Effect of Apolipoprotein E Polymorphism on the Response to Lipid-Lowering Treatment With Atorvastatin or Fenofibrate. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2006, 11, 211-221.	2.2	36
257	Smooth Muscle and Purinergic Contraction of the Human, Rabbit, Rat, and Mouse Testicular Capsule1. <i>Biology of Reproduction</i> , 2006, 74, 473-480.	2.7	36
258	Left atrial size in hypertension and stroke. <i>Journal of Hypertension</i> , 2011, 29, 1988-1993.	0.5	36
259	Lipoprotein(a) Levels in Patients With Abdominal Aortic Aneurysm. <i>Angiology</i> , 2017, 68, 99-108.	1.8	36
260	Cardiovascular disease prevention strategies for type 2 diabetes mellitus. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 1243-1260.	1.9	36
261	Associations between cardiovascular disease, cancer, and very low high-density lipoprotein cholesterol in the REasons for Geographical and Racial Differences in Stroke (REGARDS) study. <i>Cardiovascular Research</i> , 2019, 115, 204-212.	3.8	36
262	Association of statin use and clinical outcomes in heart failure patients: a systematic review and meta-analysis. <i>Lipids in Health and Disease</i> , 2019, 18, 188.	3.1	36
263	Atherogenesis in Renal Patients: A Model of Vascular Disease?. <i>Current Vascular Pharmacology</i> , 2008, 6, 93-107.	1.5	36
264	Oxidative Stress As A Common Mediator for Apoptosis Induced-Cardiac Damage in Diabetic Rats. <i>Open Cardiovascular Medicine Journal</i> , 2008, 2, 70-78.	0.4	36
265	Mean platelet volume as an indicator of platelet activation: methodological issues. <i>Platelets</i> , 2003, 14, 335-336.	2.1	35
266	Atorvastatin Decreases Triacylglycerolâ€”Associated Risk of Vascular Events in Coronary Heart Disease Patients. <i>Lipids</i> , 2007, 42, 999-1009.	1.7	35
267	ESVS Guidelines: Section A - Prevention in Patients with Carotid Stenosis. <i>Current Vascular Pharmacology</i> , 2010, 8, 673-681.	1.5	35
268	Erectile dysfunction and coronary heart disease. <i>Current Opinion in Cardiology</i> , 2015, 30, 416-421.	1.9	35
269	Nutraceutical support in heart failure: a position paper of the International Lipid Expert Panel (ILEP). <i>Nutrition Research Reviews</i> , 2020, 33, 155-179.	4.3	35
270	The Effects of Lipid-Regulating Therapy on Haemostatic Parameters. <i>Current Pharmaceutical Design</i> , 2003, 9, 2425-2443.	1.9	35

#	ARTICLE	IF	CITATIONS
271	Pioglitazone and Cancer: Angel or Demon?. <i>Current Pharmaceutical Design</i> , 2013, 19, 4913-4929.	1.9	35
272	Effect of Rosuvastatin on Non-alcoholic Steatohepatitis in Patients with Metabolic Syndrome and Hypercholesterolaemia: A Preliminary Report. <i>Current Vascular Pharmacology</i> , 2014, 12, 505-511.	1.5	35
273	Metformin and cancer: licence to heal?. <i>Expert Opinion on Investigational Drugs</i> , 2010, 19, 913-917.	4.2	34
274	Cilostazol and atherogenic dyslipidemia: a clinically relevant effect?. <i>Expert Opinion on Pharmacotherapy</i> , 2011, 12, 647-655.	1.9	34
275	Serum metalloproteinases MMP-2, MMP-9 and metalloproteinase tissue inhibitors TIMP-1 and TIMP-2 in patients on hemodialysis. <i>International Urology and Nephrology</i> , 2011, 43, 491-498.	1.5	34
276	Bilirubin Levels and Their Association with Carotid Intima Media Thickness and High-Sensitivity C-reactive Protein in Patients with Psoriasis Vulgaris. <i>American Journal of Clinical Dermatology</i> , 2014, 15, 137-142.	7.2	34
277	Non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus: Effects of statins and antidiabetic drugs. <i>Journal of Diabetes and Its Complications</i> , 2017, 31, 521-522.	2.5	34
278	Associations between risk of overall mortality, cause-specific mortality and level of inflammatory factors with extremely low and high high-density lipoprotein cholesterol levels among American adults. <i>International Journal of Cardiology</i> , 2019, 276, 242-247.	1.7	34
279	Prospective Assessment of Lower-Extremity Peripheral Arterial Disease in Diabetic Patients Using a Novel Automated Optical Device. <i>Angiology</i> , 2007, 58, 579-585.	1.8	33
280	Is type 2 diabetes mellitus a coronary heart disease equivalent or not? Do not just enjoy the debate and forget the patient!. <i>Archives of Medical Science</i> , 2019, 15, 1357-1364.	0.9	33
281	Are we ready for a gender-specific approach in interventional cardiology?. <i>International Journal of Cardiology</i> , 2019, 286, 226-233.	1.7	33
282	Pleiotropic Effects of Nicotinic Acid: Beyond High Density Lipoprotein Cholesterol Elevation. <i>Current Vascular Pharmacology</i> , 2011, 9, 385-400.	1.5	33
283	The impact of serum uric acid on cardiovascular outcomes in the LIFE study. <i>Kidney International</i> , 2004, 66, 1714-1715.	5.6	32
284	The Management of Phosphodiesterase-5 (PDE5) Inhibitor Failure. <i>Current Vascular Pharmacology</i> , 2006, 4, 89-93.	1.5	32
285	Effect of milrinone on human platelet shape change, aggregation and thromboxane A2 synthesis: An in vitro study. <i>Thrombosis Research</i> , 1993, 71, 227-236.	1.7	31
286	Metabolic syndrome and gender differences in postprandial lipaemia. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2006, 13, 661-664.	2.8	31
287	Leptin: A Promising Therapeutic Target with Pleiotropic Action Besides Body Weight Regulation. <i>Current Drug Targets</i> , 2006, 7, 761-771.	2.3	31
288	Combined Treatment With Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers: A Review of the Current Evidence. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2006, 11, 1-15.	2.2	31

#	ARTICLE	IF	CITATIONS
289	Non-low-density lipoprotein cholesterol-associated actions of ezetimibe: an overview. <i>Expert Opinion on Therapeutic Targets</i> , 2006, 10, 851-866.	3.4	31
290	Ezetimibe; More Than a Low Density Lipoprotein Cholesterol Lowering Drug? An Update After 4 Years. <i>Current Vascular Pharmacology</i> , 2011, 9, 62-86.	1.5	31
291	Egg Consumption and Risk of Total and Cause-Specific Mortality: An Individual-Based Cohort Study and Pooling Prospective Studies on Behalf of the Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC) Group. <i>Journal of the American College of Nutrition</i> , 2019, 38, 552-563.	3.1	31
292	The Effect of Statins on Postprandial Lipemia. <i>Current Drug Targets</i> , 2007, 8, 551-560.	2.3	30
293	Thromboangiitis Obliterans (Buerger's Disease): Searching for a Therapeutic Strategy. <i>Angiology</i> , 2007, 58, 75-84.	1.8	30
294	Regulation of inducible nitric oxide synthase activity/expression in rat hearts from ghrelin-treated rats. <i>Journal of Physiology and Biochemistry</i> , 2011, 67, 195-204.	3.1	30
295	In-hospital mortality for pulmonary embolism: relationship with chronic kidney disease and end-stage renal disease. The hospital admission and discharge database of the Emilia Romagna region of Italy. <i>Internal and Emergency Medicine</i> , 2013, 8, 735-740.	2.3	30
296	Dietary patterns, plasma vitamins and Trans fatty acids are associated with peripheral artery disease. <i>Lipids in Health and Disease</i> , 2017, 16, 254.	3.1	30
297	Effect of statins and aspirin alone and in combination on clinical outcome in dyslipidaemic patients with coronary heart disease. A subgroup analysis of the GREACE study. <i>Platelets</i> , 2005, 16, 65-71.	2.1	29
298	Primary and Secondary Hypertriglyceridaemia. <i>Current Drug Targets</i> , 2009, 10, 336-343.	2.3	29
299	The effects of rosuvastatin alone or in combination with fenofibrate or omega 3 fatty acids on inflammation and oxidative stress in patients with mixed dyslipidemia. <i>Expert Opinion on Pharmacotherapy</i> , 2011, 12, 2605-2611.	1.9	29
300	Peroxisome Proliferator-Activated Receptors and Atherosclerosis. <i>Angiology</i> , 2011, 62, 523-534.	1.8	29
301	Subclinical hypothyroidism and vascular risk: An update. <i>Hormones</i> , 2013, 12, 495-506.	2.1	29
302	Abnormal Peri-Organ or Intra-Organ Fat Deposition and Vascular Risk. <i>Angiology</i> , 2018, 69, 841-842.	1.8	29
303	The Epsilon 2 and 4 Alleles of Apolipoprotein E and Ischemic Vascular Events in the Greek Population – Implications for the Interpretation of Similar Studies. <i>Angiology</i> , 2003, 54, 51-58.	1.8	28
304	The Effect of a Loading Dose (300 mg) of Clopidogrel on Platelet Function in Patients with Peripheral Arterial Disease. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2003, 9, 115-120.	1.7	28
305	Endothelin-1 and Human Platelets. <i>Current Vascular Pharmacology</i> , 2005, 3, 393-399.	1.5	28
306	Anti-Inflammatory Effects of Fibrates: An Overview. <i>Current Medicinal Chemistry</i> , 2009, 16, 676-684.	2.5	28

#	ARTICLE	IF	CITATIONS
307	Triglycerides and Vascular Risk: Insights from Epidemiological Data and Interventional Studies. <i>Current Drug Targets</i> , 2009, 10, 320-327.	2.3	28
308	Optimal statin type and dosage for vascular patients. <i>Journal of Vascular Surgery</i> , 2011, 53, 837-844.	1.1	28
309	Perioperative/Periprocedural Effects of Statin Treatment for Patients Undergoing Vascular Surgery or Endovascular Procedures: An Update. <i>Current Vascular Pharmacology</i> , 2013, 11, 112-120.	1.5	28
310	Dyslipidaemia in type 2 diabetes mellitus. <i>Current Opinion in Cardiology</i> , 2017, 32, 422-429.	1.9	28
311	The Relation Between No-Reflow Phenomenon and Complete Blood Count Parameters. <i>Angiology</i> , 2017, 68, 381-388.	1.8	28
312	Association between phenotypic familial hypercholesterolaemia and telomere length in US adults: results from a multi-ethnic survey. <i>European Heart Journal</i> , 2018, 39, 3635-3640.	2.4	28
313	Association of ideal cardiovascular health metrics with serum uric acid, inflammation and atherogenic index of plasma: A population-based survey. <i>Atherosclerosis</i> , 2019, 284, 44-49.	0.9	28
314	Associations of serum uric acid with total and cause-specific mortality: Findings from individuals and pooling prospective studies. <i>Atherosclerosis</i> , 2020, 296, 49-58.	0.9	28
315	Treating dyslipidaemia in non-insulin-dependent diabetes mellitus – a special reference to statins. <i>Journal of Diabetes and Its Complications</i> , 2001, 15, 211-226.	2.5	27
316	The role of serotonin in tumour growth (Review). <i>Oncology Reports</i> , 2005, 14, 1593.	2.6	27
317	Identifying and Attaining LDL-C Goals: Mission Accomplished? Next Target: New Therapeutic Options to Raise HDL-C Levels. <i>Current Drug Targets</i> , 2007, 8, 483-488.	2.3	27
318	Are Statins an Option in the Management of Abdominal Aortic Aneurysms?. <i>Vascular and Endovascular Surgery</i> , 2008, 42, 128-134.	0.7	27
319	Effect of Non-Statins Lipid Lowering and Anti-Obesity Drugs on LDL Subfractions in Patients with Mixed Dyslipidaemia. <i>Current Vascular Pharmacology</i> , 2010, 8, 820-830.	1.5	27
320	The role of ankle brachial index and carotid intima-media thickness in vascular risk stratification. <i>Current Opinion in Cardiology</i> , 2010, 25, 394-398.	1.9	27
321	Seasonal variation in the occurrence of stroke in Northern Greece: a 10 year study in 8204 patients. <i>Neurological Research</i> , 2010, 32, 326-331.	1.4	27
322	Iatrogenic hyperhomocysteinemia in patients with metabolic syndrome: A systematic review and metaanalysis. <i>Atherosclerosis</i> , 2011, 214, 11-19.	0.9	27
323	Statins and new-onset diabetes mellitus – a matter for debate. <i>Nature Reviews Endocrinology</i> , 2012, 8, 133-134.	9.7	27
324	Long-Term Impact of Multifactorial Treatment on New-Onset Diabetes and Related Cardiovascular Events in Metabolic Syndrome. <i>Angiology</i> , 2012, 63, 358-366.	1.8	27

#	ARTICLE	IF	CITATIONS
325	Metformin and heart failure: never say never again. <i>Expert Opinion on Pharmacotherapy</i> , 2012, 13, 1-8.	1.9	27
326	The influence of atorvastatin on parameters of inflammation left ventricular function, hospitalizations and mortality in patients with dilated cardiomyopathy – 5-year follow-up. <i>Lipids in Health and Disease</i> , 2013, 12, 47.	3.1	27
327	New statin guidelines and promising novel therapeutics. <i>Nature Reviews Cardiology</i> , 2014, 11, 72-74.	13.9	27
328	Vitamin D status and circulating biomarkers of endothelial dysfunction and inflammation in non-diabetic obese individuals: a pilot study. <i>Archives of Medical Science</i> , 2017, 1, 53-60.	0.9	27
329	Statin loading in cardiovascular surgery. <i>Current Opinion in Cardiology</i> , 2018, 33, 436-443.	1.9	27
330	Efficacy and safety of statin use in children and adolescents with familial hypercholesterolaemia: a systematic review and meta-analysis of randomized-controlled trials. <i>Endocrine</i> , 2020, 69, 249-261.	2.4	27
331	Endothelial Dysfunction in Dyslipidaemia: Molecular Mechanisms and Clinical Implications. <i>Current Medicinal Chemistry</i> , 2020, 27, 1021-1040.	2.5	27
332	Alcohol and the Cardiovascular System: A Double-Edged Sword. <i>Current Pharmaceutical Design</i> , 2014, 20, 6276-6288.	1.9	27
333	Statin-Induced Increase in HDL-C and Renal Function in Coronary Heart Disease Patients. <i>Open Cardiovascular Medicine Journal</i> , 2007, 1, 8-14.	0.4	27
334	Down-regulation of endothelin-B receptor sites in cavernosal tissue of a rabbit model of partial bladder outlet obstruction: potential clinical relevance. <i>World Journal of Urology</i> , 1999, 17, 290-295.	2.4	26
335	Alcohol Use, Vascular Disease, and Lipid-Lowering Drugs. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2006, 318, 1-7.	2.6	26
336	Endothelial Dysfunction in Patients with Noncomplicated and Complicated Hypertension. <i>Clinical and Experimental Hypertension</i> , 2009, 31, 20-30.	1.3	26
337	Natural History of Cardiomyopathy in Adult Dogs With Golden Retriever Muscular Dystrophy. <i>Journal of the American Heart Association</i> , 2019, 8, e012443.	3.9	26
338	Treatment of Dyslipidaemias in Patients with Established Vascular Disease: A Revival of the Fibrates. <i>Current Medical Research and Opinion</i> , 2000, 16, 21-32.	2.0	26
339	The Treatment of Hypertension in Patients with Erectile Dysfunction. <i>Current Medical Research and Opinion</i> , 2000, 16, s31-s36.	2.0	25
340	The Choice of Antihypertensive Drugs in Patients with Erectile Dysfunction. <i>Current Medical Research and Opinion</i> , 2002, 18, 103-107.	2.0	25
341	Analysis of antihypertensive effects of statins. <i>Current Hypertension Reports</i> , 2007, 9, 175-183.	3.4	25
342	Editorial: [Pleiotropic Effects of Statins: Implications for a Wide Range of Diseases]. <i>Current Vascular Pharmacology</i> , 2008, 6, 237-239.	1.5	25

#	ARTICLE	IF	CITATIONS
343	Effects of statin treatment on endothelial function, oxidative stress and inflammation in patients with arterial hypertension and normal cholesterol levels. <i>Journal of Hypertension</i> , 2011, 29, 2493-2494.	0.5	25
344	Editorial [Hot Topic: New Developments in the Prevention and Treatment of Vascular Disease - 2 Executive (Guest Editors: Manfredi Rizzo and Dimitri P. Mikhailidis)]. <i>Current Pharmaceutical Design</i> , 2011, 17, 3608-3610.	1.9	25
345	Ear lobe crease: a marker of coronary artery disease?. <i>Archives of Medical Science</i> , 2015, 6, 1145-1155.	0.9	25
346	How effective are the ESC/EAS and 2013 ACC/AHA guidelines in treating dyslipidemia? Lessons from a lipid clinic. <i>Current Medical Research and Opinion</i> , 2015, 31, 221-228.	2.0	25
347	New-Onset Diabetes and Statins: Throw the Bath Water Out, But, Please, Keep the Baby!. <i>Metabolism: Clinical and Experimental</i> , 2015, 64, 471-475.	3.7	25
348	Efficacy of Statin Therapy in Pulmonary Arterial Hypertension: A Systematic Review and Meta-Analysis. <i>Scientific Reports</i> , 2016, 6, 30060.	3.5	25
349	Muscarinic stimulation of prostacyclin synthesis by the rat penis. <i>European Journal of Pharmacology</i> , 1986, 123, 67-71.	3.6	24
350	The role of renin-angiotensin system inhibition in the treatment of hypertension in metabolic syndrome: are all the angiotensin receptor blockers equal?. <i>Expert Opinion on Therapeutic Targets</i> , 2007, 11, 191-205.	3.4	24
351	Medical treatment as an alternative to adrenalectomy in patients with aldosterone-producing adenomas. <i>Endocrine-Related Cancer</i> , 2008, 15, 693-700.	3.4	24
352	Effects of statin treatment in men and women with stable coronary heart disease: a subgroup analysis of the GREACE Study. <i>Current Medical Research and Opinion</i> , 2008, 24, 1593-1599.	2.0	24
353	Aggressive statin treatment, very low serum cholesterol levels and haemorrhagic stroke: is there an association?. <i>Current Opinion in Cardiology</i> , 2010, 25, 406-410.	1.9	24
354	Is Bilirubin a Marker of Vascular Disease and/or Cancer and is it a Potential Therapeutic Target?. <i>Current Pharmaceutical Design</i> , 2011, 17, 3644-3655.	1.9	24
355	Short-term statin therapy for prevention of contrast-induced AKI. <i>Nature Reviews Nephrology</i> , 2014, 10, 8-9.	9.7	24
356	Increased Urinary Excretion of Podocyte Markers in Normoalbuminuric Patients with Diabetes. <i>Nephron</i> , 2015, 131, 34-42.	1.8	24
357	Contrast-Induced Acute Kidney Injury in Patients Undergoing Carotid Artery Stenting: An Underestimated Issue. <i>Angiology</i> , 2017, 68, 752-756.	1.8	24
358	Lung and kidney: a dangerous liaison? A population-based cohort study in COPD patients in Italy. <i>International Journal of COPD</i> , 2017, Volume 12, 443-450.	2.3	24
359	Homocysteine and Non-Cardiac Vascular Disease. <i>Current Pharmaceutical Design</i> , 2017, 23, 3224-3232.	1.9	24
360	Higher dietary acid load is associated with higher likelihood of peripheral arterial disease among American adults. <i>Journal of Diabetes and Its Complications</i> , 2018, 32, 565-569.	2.5	24

#	ARTICLE	IF	CITATIONS
361	Postprandial Hypertriglyceridaemia Revisited in the Era of Non-fasting Lipid Profiles: Executive Summary of a 2019 Expert Panel Statement. <i>Current Vascular Pharmacology</i> , 2019, 17, 538-540.	1.5	24
362	A Review of the Cardiovascular and Anti-Atherogenic Effects of Ghrelin. <i>Current Pharmaceutical Design</i> , 2013, 19, 4953-4963.	1.9	24
363	Naftidrofuryl inhibits the release of 5-hydroxytryptamine and platelet-derived growth factor from human platelets. <i>Clinica Chimica Acta</i> , 1994, 230, 157-167.	1.6	23
364	Drug Treatment of Combined Hyperlipidemia. <i>American Journal of Cardiovascular Drugs</i> , 2001, 1, 327-336.	2.4	23
365	Effect of Atorvastatin on Serum Creatinine Levels. <i>Current Medical Research and Opinion</i> , 2001, 17, 230-231.	2.0	23
366	Association of Apolipoprotein E Genotype with Early Onset of Coronary Heart Disease in Greek Men. <i>Angiology</i> , 2005, 56, 663-670.	1.8	23
367	The involvement of professional medical writers in medical publications. <i>Current Medical Research and Opinion</i> , 2005, 21, 307-309.	2.0	23
368	Atherosclerotic Renal Artery Stenosis: Association with Emerging Vascular Risk Factors. <i>Nephron Clinical Practice</i> , 2008, 108, c56-c66.	2.1	23
369	Naltrexone sustained-release (SR) + bupropion SR combination therapy for the treatment of obesity: "A new kid on the block"? <i>Annals of Medicine</i> , 2011, 43, 249-258.	3.9	23
370	Editorial (Should Chronic Kidney Disease be Considered as a Coronary Heart Disease Equivalent?). <i>Current Vascular Pharmacology</i> , 2012, 10, 374-377.	1.5	23
371	Are statins "IDEAL" for non-alcoholic fatty liver disease?. <i>Current Medical Research and Opinion</i> , 2014, 30, 229-231.	2.0	23
372	Thromboprophylaxis in Patients with COVID-19: Systematic Review of National and International Clinical Guidance Reports. <i>Current Vascular Pharmacology</i> , 2022, 20, 96-110.	1.5	23
373	Lipids, Statins and Heart Failure: An Update. <i>Current Pharmaceutical Design</i> , 2016, 22, 4796-4806.	1.9	23
374	Cholesteryl Ester Transfer Protein Gene Polymorphisms and Longevity Syndrome. <i>Open Cardiovascular Medicine Journal</i> , 2010, 4, 14-19.	0.4	23
375	Statin plus ezetimibe treatment in clinical practice: the SI-SPECT (Slovenia (SI) Statin Plus Ezetimibe in) Tj ETQq1 1 0.784314 rgBT /Over 2008, 24, 2467-2476.	2.0	22
376	The Role of Statins for the Primary and Secondary Prevention of Coronary Heart Disease in Women. <i>Current Pharmaceutical Design</i> , 2009, 15, 1054-1062.	1.9	22
377	Diabetes and Antioxidants: Myth or Reality?. <i>Current Vascular Pharmacology</i> , 2010, 8, 661-672.	1.5	22
378	Contrast-Induced Nephropathy and the Vascular Patient. <i>Angiology</i> , 2010, 61, 721-723.	1.8	22

#	ARTICLE	IF	CITATIONS
379	Statin loading in patients undergoing percutaneous coronary intervention for acute coronary syndromes: a new pleiotropic effect?. <i>Current Medical Research and Opinion</i> , 2010, 26, 839-842.	2.0	22
380	Could carbon monoxide and bilirubin be friends as well as foes of the body?. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2010, 70, 1-5.	1.2	22
381	Lipid Lowering Drugs and Gallstones: A Therapeutic Option?. <i>Current Pharmaceutical Design</i> , 2011, 17, 3622-3631.	1.9	22
382	Statins and noncardiac vascular disease. <i>Current Opinion in Cardiology</i> , 2012, 27, 392-397.	1.9	22
383	Association Between Epicardial Fat Thickness and Weight Homeostasis Hormones in Patients With Noncachectic Heart Failure. <i>Angiology</i> , 2013, 64, 173-180.	1.8	22
384	New therapies to reduce low-density lipoprotein cholesterol. <i>Current Opinion in Cardiology</i> , 2013, 28, 452-457.	1.9	22
385	Effects of oral hypoglycemic agents on platelet function. <i>Journal of Diabetes and Its Complications</i> , 2015, 29, 846-851.	2.5	22
386	Assessment of postprandial triglycerides in clinical practice: Validation in a general population and coronary heart disease patients. <i>Journal of Clinical Lipidology</i> , 2016, 10, 1163-1171.	1.6	22
387	The effect of statins on cardiovascular outcomes by smoking status: A systematic review and meta-analysis of randomized controlled trials. <i>Pharmacological Research</i> , 2017, 122, 105-117.	7.3	22
388	Lipid-lowering agents for concurrent cardiovascular and chronic kidney disease. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 2007-2017.	1.9	22
389	The Role of n-3 Fatty Acids in Cardiovascular Disease: Back to the Future. <i>Angiology</i> , 2020, 71, 10-16.	1.8	22
390	Adverse Impact of <i>Desulfovibrio</i> spp. and Beneficial Role of <i>Anaerostipes</i> spp. on Renal Function: Insights from a Mendelian Randomization Analysis. <i>Nutrients</i> , 2020, 12, 2216.	4.2	22
391	Management of Patients with Asymptomatic Carotid Stenosis May Need to Be Individualized: A Multidisciplinary Call for Action. <i>Journal of Stroke</i> , 2021, 23, 202-212.	3.3	22
392	Pharmacogenetic study of cholesteryl ester transfer protein gene and simvastatin treatment in hypercholesterolaemic subjects. <i>Expert Opinion on Pharmacotherapy</i> , 2007, 8, 2459-2463.	1.9	21
393	Point of care testing is appropriate for National Health Service health check. <i>Annals of Clinical Biochemistry</i> , 2011, 48, 159-165.	1.6	21
394	Dronedarone: An overview. <i>Annals of Medicine</i> , 2012, 44, 60-72.	3.9	21
395	Hypertension and kidney disease. <i>Journal of Hypertension</i> , 2012, 30, 457-462.	0.5	21
396	Cardiovascular Risk Assessment in Diabetes Mellitus. <i>Angiology</i> , 2013, 64, 336-342.	1.8	21

#	ARTICLE	IF	CITATIONS
397	Differences in metabolic parameters and cardiovascular risk between American Diabetes Association and World Health Organization definition of impaired fasting glucose in European Caucasian subjects: a cross-sectional study. <i>Archives of Medical Science</i> , 2013, 5, 788-795.	0.9	21
398	Mean Platelet Volume and Platelet Distribution Width in Patients With Obstructive Sleep Apnea Syndrome and Concurrent Chronic Obstructive Pulmonary Disease. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2018, 24, 1216-1222.	1.7	21
399	Cilostazol for intermittent claudication. <i>The Cochrane Library</i> , 2021, 2021, CD003748.	2.9	21
400	Combination of Statin Plus Renin Angiotensin System Inhibition for the Prevention or the Treatment of Atherosclerotic Cardiovascular Disease. <i>Current Pharmaceutical Design</i> , 2014, 20, 6299-6305.	1.9	21
401	Upregulation of Endothelin A Receptor Sites in the Rabbit Diabetic Kidney: Potential Relevance to the Early Pathogenesis of Diabetic Nephropathy. <i>Nephron</i> , 1999, 83, 261-267.	1.8	20
402	Metallothionein expression in the high-risk carotid atherosclerotic plaque. <i>Current Medical Research and Opinion</i> , 2007, 23, 659-670.	2.0	20
403	Association between plasma levels and immunolocalization of cytokines in heart valve lesions: a possible target for treatment?. <i>Expert Opinion on Therapeutic Targets</i> , 2008, 12, 1209-1215.	3.4	20
404	Cardiovascular events in chronic dialysis patients: emphasizing the importance of vascular disease prevention. <i>International Urology and Nephrology</i> , 2010, 42, 999-1006.	1.5	20
405	A PRISMA-compliant systematic review and meta-analysis of randomized controlled trials investigating the effects of statin therapy on plasma lipid concentrations in HIV-infected patients. <i>Pharmacological Research</i> , 2016, 111, 343-356.	7.3	20
406	Proscarpogenic Effects of Statins May Limit Their Effectiveness in Patients with Heart Failure. <i>Trends in Pharmacological Sciences</i> , 2018, 39, 331-353.	8.8	20
407	Motor sequence learning and intermanual transfer with a phantom limb. <i>Cortex</i> , 2018, 101, 181-191.	2.7	20
408	Link between plasma trans-fatty acid and fatty liver is moderated by adiposity. <i>International Journal of Cardiology</i> , 2018, 272, 316-322.	1.7	20
409	Dietary choline is positively related to overall and cause-specific mortality: results from individuals of the National Health and Nutrition Examination Survey and pooling prospective data. <i>British Journal of Nutrition</i> , 2019, 122, 1262-1270.	2.4	20
410	Impact of glucagon-like peptide 1 receptor agonists and sodium-glucose transport protein 2 inhibitors on blood pressure and lipid profile. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 2125-2135.	1.9	20
411	Can We Decrease Epicardial and Pericardial Fat in Patients With Diabetes?. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2021, 26, 107424842110069.	2.2	20
412	The prevalence of cardiovascular risk factors and cardiovascular disease among primary care patients in Poland: results from the LIPIDOGRAM2015 study. <i>Atherosclerosis Supplements</i> , 2020, 42, e15-e24.	1.4	20
413	Lipoprotein (a) and Cardiovascular Risk: The Show Must go on. <i>Current Medicinal Chemistry</i> , 2017, 24, 989-1006.	2.5	20
414	Psoriasis and Vascular Risk: An Update. <i>Current Pharmaceutical Design</i> , 2014, 20, 6114-6125.	1.9	20

#	ARTICLE	IF	CITATIONS
415	Evaluation of Aortic Stiffness (Aortic Pulse-Wave Velocity) Before and After Elective Abdominal Aortic Aneurysm Repair Procedures: A Pilot Study#. <i>Open Cardiovascular Medicine Journal</i> , 2009, 3, 173-175.	0.4	20
416	The Role of Psychobiological and Neuroendocrine Mechanisms in Appetite Regulation and Obesity. <i>Open Cardiovascular Medicine Journal</i> , 2012, 6, 147-155.	0.4	20
417	Effect of milrinone on thromboxane A2 synthesis, cAMP phosphodiesterase and 45Ca ²⁺ uptake by human platelets. <i>European Journal of Pharmacology</i> , 1993, 245, 67-73.	2.6	19
418	Do Different Vascular Risk Factors Affect All Arteries Equally?. <i>Angiology</i> , 2008, 59, 397-401.	1.8	19
419	Editorial [Carotid Intima-Media Thickness and Ezetimibe: The End of a Misunderstanding?]. <i>Current Vascular Pharmacology</i> , 2011, 9, 381-384.	1.5	19
420	Evaluation of the Possible Contribution of Antioxidants Administration in Metabolic Syndrome. <i>Current Pharmaceutical Design</i> , 2011, 17, 3699-3712.	1.9	19
421	Review: Antiplatelet Drugs: What Comes Next?. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2011, 17, 9-26.	1.7	19
422	The Rationale for Lowering the Size Threshold in Elective Endovascular Repair of Abdominal Aortic Aneurysm. <i>Journal of Endovascular Therapy</i> , 2011, 18, 308-313.	1.7	19
423	Aging Men and Lipids. <i>American Journal of Men's Health</i> , 2011, 5, 152-165.	1.6	19
424	Optimal contemporary management of symptomatic and asymptomatic carotid artery stenosis. <i>Vascular</i> , 2011, 19, 117-120.	0.9	19
425	All for Statins and Statins for All; An Update. <i>Current Pharmaceutical Design</i> , 2015, 22, 18-27.	1.9	19
426	Endocan and Atherosclerosis. <i>Angiology</i> , 2015, 66, 490-490.	1.8	19
427	Fibroblast growth factor 19-targeted therapies for the treatment of metabolic disease. <i>Expert Opinion on Investigational Drugs</i> , 2015, 24, 603-610.	4.2	19
428	Proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors: Shaping the future after the further cardiovascular outcomes research with PCSK9 inhibition in subjects with elevated risk (FOURIER) trial. <i>Metabolism: Clinical and Experimental</i> , 2017, 74, 43-46.	3.7	19
429	Effect of statin therapy on plasma apolipoprotein CIII concentrations: A systematic review and meta-analysis of randomized controlled trials. <i>Journal of Clinical Lipidology</i> , 2018, 12, 801-809.	1.6	19
430	Increased risk for cardiovascular disease in patients with obstructive sleep apnoea syndrome—chronic obstructive pulmonary disease (overlap syndrome). <i>Clinical Respiratory Journal</i> , 2019, 13, 708-715.	1.7	19
431	Aortic Stiffening Is an Extraintestinal Manifestation of Inflammatory Bowel Disease: Review of the Literature and Expert Panel Statement. <i>Angiology</i> , 2020, 71, 689-697.	1.8	19
432	The Impact of Smoking on Cardiovascular Outcomes and Comorbidities in Statin-treated Patients with Coronary Artery Disease: A Post hoc Analysis of the GREACE Study. <i>Current Vascular Pharmacology</i> , 2013, 11, 779-784.	1.5	19

#	ARTICLE	IF	CITATIONS
433	Postprandial Hypertriglyceridaemia Revisited in the Era of Non-Fasting Lipid Profile Testing: A 2019 Expert Panel Statement, Narrative Review. <i>Current Vascular Pharmacology</i> , 2019, 17, 515-537.	1.5	19
434	Altered prostacyclin synthesis by aortae from hepatic portal vein-constricted rats: evidence for effects on protein kinase C and calcium. <i>Journal of Hepatology</i> , 1994, 21, 1017-1022.	4.0	18
435	Relaxation of rabbit lower urinary tract smooth muscle by nitric oxide and carbon monoxide: modulation by hydrogen peroxide. <i>European Journal of Pharmacology</i> , 2000, 387, 329-335.	3.6	18
436	The Influence of Natural Menopause on Postprandial Lipemia in Heterozygotes for Familial Hypercholesterolemia. <i>Journal of Women's Health</i> , 2004, 13, 1119-1126.	3.4	18
437	Statins and renal function. Is the compound and dose making a difference?. <i>Nephrology Dialysis Transplantation</i> , 2007, 22, 963-964.	0.8	18
438	Association between the TaqIB polymorphism in the cholesteryl ester transfer protein gene locus and postprandial plasma lipoprotein levels in heterozygotes for familial hypercholesterolemia. <i>Clinical Chemistry and Laboratory Medicine</i> , 2007, 45, 1190-8.	2.4	18
439	<i>Cholesterol Crystal Embolization</i> : A Possible Complication of Peripheral Endovascular Interventions. <i>Journal of Endovascular Therapy</i> , 2008, 15, 614-625.	1.7	18
440	Radial Artery Catheterization for Percutaneous Vascular or Coronary Interventions: An Innocent Procedure?. <i>Angiology</i> , 2010, 61, 5-7.	1.8	18
441	Pulmonary arterial hypertension and statins: an update. <i>Current Opinion in Cardiology</i> , 2011, 26, 322-326.	1.9	18
442	Lipid Lowering Agents and the Endothelium: An Update after 4 Years. <i>Current Vascular Pharmacology</i> , 2012, 10, 33-41.	1.5	18
443	Letter to the Editor Obstructive sleep apnoea syndrome and cardiovascular risk. <i>Archives of Medical Science</i> , 2012, 6, 1115-1116.	0.9	18
444	Statin therapy in athletes and patients performing regular intense exercise – Position paper from the International Lipid Expert Panel (ILEP). <i>Pharmacological Research</i> , 2020, 155, 104719.	7.3	18
445	Perivascular Adipose Tissue: Pathophysiological Links With Inflammation, Atherosclerosis, and Thrombosis. <i>Angiology</i> , 2022, 73, 195-196.	1.8	18
446	The Challenges in Moving from Ageing to Successful Longevity. <i>Current Vascular Pharmacology</i> , 2013, 12, 662-673.	1.5	18
447	Direct measurement of hepatic tissue hypoxia by using a novel $t\text{c}^{18}\text{O}_2$ monitoring system in comparison with near-infrared spectroscopy. <i>Liver International</i> , 2003, 23, 163-170.	4.0	17
448	Effect of Antihypertensive Treatment on Plasma Fibrinogen and Serum HDL Levels in Patients with Essential Hypertension. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2005, 11, 139-146.	1.7	17
449	Doxazosin and Serotonin (5-HT) Receptor (1A, 2A, and 4) Antagonists Inhibit 5-HT-Mediated Human Cavernosal Contraction. <i>Journal of Andrology</i> , 2006, 27, 679-685.	1.9	17
450	Pharmacological treatment of non-alcoholic steatohepatitis: The current evidence. <i>Scandinavian Journal of Gastroenterology</i> , 2007, 42, 139-147.	1.5	17

#	ARTICLE	IF	CITATIONS
451	Should a statin be prescribed to every patient with heart failure?. Heart Failure Reviews, 2008, 13, 211-225.	4.0	17
452	Editorial Are we getting to lipid targets in real life?. Archives of Medical Science, 2010, 5, 639-641.	0.9	17
453	Effect of Angiotensin II and its Receptor Antagonists on Human Corpus Cavernous Contractility and Oxidative Stress: Modulation of Nitric Oxide Mediated Relaxation. Journal of Urology, 2011, 185, 2414-2420.	3.9	17
454	Obstructive Sleep Apnea and Cardiovascular Risk. Angiology, 2012, 63, 569-573.	1.8	17
455	Prevalence of Metabolic Syndrome According to Different Definitions in a Hypertensive Population. Angiology, 2012, 63, 39-47.	1.8	17
456	Editorial Lipid-lowering therapies and achievement of LDL-cholesterol targets. Archives of Medical Science, 2012, 4, 598-600.	0.9	17
457	Contrast-induced acute kidney injury in diabetes mellitus: Clinical relevance and predisposing factors. Could statins be of benefit?. Journal of Diabetes and Its Complications, 2018, 32, 982-984.	2.5	17
458	Perirenal Adiposity and Other Excessive Intra- and Peri-Organ Fat Depots: What Is the Connection?. Angiology, 2019, 70, 581-583.	1.8	17
459	Diabetes Mellitus and Chronic Obstructive Pulmonary Disease: An Overview. Experimental and Clinical Endocrinology and Diabetes, 2021, 129, 699-704.	1.3	17
460	Endocan: a new marker of endothelial function. Current Opinion in Cardiology, 2021, 36, 462-468.	1.9	17
461	Colesevelam: A New and Improved Bile Acid Sequestrant?. Current Pharmaceutical Design, 2013, 19, 3115-3123.	1.9	17
462	Endocrine Hypertension: Diagnosis and Management of a Complex Clinical Entity. Current Vascular Pharmacology, 2010, 8, 646-660.	1.5	17
463	The Impact of Lower Extremity Venous Ulcers due to Chronic Venous Insufficiency on Quality of Life~!2008-11-17~!2008-11-19~!2008-11-28~!. Open Cardiovascular Medicine Journal, 2008, 2, 105-109.	0.4	17
464	Differential inhibitory potencies of non-steroidal antiinflammatory drugs on smooth muscle prostanoid synthesis. European Journal of Pharmacology, 1990, 182, 83-89.	3.6	16
465	Attaining United Kingdom-European Atherosclerosis Society Low-density Lipoprotein Cholesterol Guideline Target Values in the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study. Current Medical Research and Opinion, 2002, 18, 499-502.	2.0	16
466	Clinical significance of carotid bruits: an innocent finding or a useful warning sign?. Neurological Research, 2008, 30, 523-530.	1.4	16
467	High Density Lipoprotein Cholesterol and Statin Trials. Current Medicinal Chemistry, 2008, 15, 2265-2270.	2.5	16
468	Lipid-lowering agents and new onset diabetes mellitus. Expert Opinion on Pharmacotherapy, 2010, 11, 1965-1970.	1.9	16

#	ARTICLE	IF	CITATIONS
469	Ezetimibe in diabetes: more than cholesterol lowering?. <i>Current Medical Research and Opinion</i> , 2010, 26, 2517-2520.	2.0	16
470	Non-alcoholic fatty liver disease and colorectal cancer: A marker of risk or common causation?. <i>Metabolism: Clinical and Experimental</i> , 2018, 87, A10-A13.	3.7	16
471	Management of Statin-Intolerant High-Risk Patients. <i>Current Vascular Pharmacology</i> , 2010, 8, 632-637.	1.5	16
472	Uric Acid Metabolism in Pre-hypertension and the Metabolic Syndrome. <i>Current Vascular Pharmacology</i> , 2014, 12, 572-585.	1.5	16
473	Implementation of Guidelines for the Management of Arterial Hypertension. The Impulsion Study. <i>Open Cardiovascular Medicine Journal</i> , 2009, 3, 26-34.	0.4	16
474	Hypoglycaemia and Cardiovascular Disease Risk in Patients with Diabetes. <i>Current Pharmaceutical Design</i> , 2020, 26, 5637-5649.	1.9	16
475	Improvement of Ketoacidosis in the Diabetic Rat after the Administration of the Oral Antilipolytic Agent Gr 79236. <i>Clinical Science</i> , 1994, 86, 593-598.	4.4	15
476	Doxazosin modifies serotonin-mediated rabbit urinary bladder contraction. <i>Urological Research</i> , 2000, 28, 116-121.	1.5	15
477	Relationship between LDL-C and non-HDL-C levels and clinical outcome in the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. <i>Current Medical Research and Opinion</i> , 2004, 20, 1385-1392.	2.0	15
478	Omega-3 fatty acids: How can they be used in secondary prevention?. <i>Current Atherosclerosis Reports</i> , 2008, 10, 510-517.	4.9	15
479	A functional study of purinergic signalling in the normal and pathological rabbit corpus cavernosum. <i>BJU International</i> , 2008, 101, 1043-1047.	2.8	15
480	Vernakalant hydrochloride for the treatment of atrial fibrillation. <i>Expert Opinion on Investigational Drugs</i> , 2009, 18, 1929-1937.	4.2	15
481	Stage of chronic kidney disease and severity of coronary heart disease manifestation. <i>Expert Opinion on Pharmacotherapy</i> , 2012, 13, 457-460.	1.9	15
482	High-intensity statin therapy and regression of coronary atherosclerosis in patients with diabetes mellitus. <i>Journal of Diabetes and Its Complications</i> , 2015, 29, 142-145.	2.5	15
483	Cardiovascular effects of sodium-glucose cotransporter 2 inhibitors: multiple actions. <i>Current Medical Research and Opinion</i> , 2016, 32, 1513-1514.	2.0	15
484	Adiposity May Moderate the Link Between Choline Intake and Non-alcoholic Fatty Liver Disease. <i>Journal of the American College of Nutrition</i> , 2019, 38, 633-639.	3.1	15
485	Predictive models with the use of omics and supervised machine learning to diagnose non-alcoholic fatty liver disease: A non-invasive alternative to liver biopsy?. <i>Metabolism: Clinical and Experimental</i> , 2019, 101, 154010.	3.7	15
486	Diabetes and carotid artery disease: a narrative review. <i>Annals of Translational Medicine</i> , 2020, 8, 1280-1280.	1.7	15

#	ARTICLE	IF	CITATIONS
487	Microalbuminuria: A Neglected Cardiovascular Risk Factor in Non-diabetic Individuals?. <i>Current Pharmaceutical Design</i> , 2013, 19, 4964-4980.	1.9	15
488	Benefits and drawbacks of statins and non-statin lipid lowering agents in carotid artery disease. <i>Progress in Cardiovascular Diseases</i> , 2022, 73, 41-47.	3.7	15
489	Time-dependent up-regulation of neuronal 5-hydroxytryptamine binding sites in the detrusor of a rabbit model of partial bladder outlet obstruction. <i>World Journal of Urology</i> , 1999, 17, 255-260.	2.4	14
490	Combination Antiplatelet Therapy in Patients with Peripheral Vascular Bypass Grafts. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2004, 10, 9-18.	1.7	14
491	Effect of tibolone on markers of cardiovascular disease risk in postmenopausal women undergoing hemodialysis: a pilot study. <i>Fertility and Sterility</i> , 2004, 81, 1624-1631.	1.0	14
492	The Effect of Cholesterol-Lowering Treatment on Renal Function. <i>American Journal of Kidney Diseases</i> , 2006, 47, 561.	2.0	14
493	Experimental Models of Abdominal Aortic Aneurysms: An Overview. <i>Current Pharmaceutical Design</i> , 2008, 14, 325-337.	1.9	14
494	Cardiovascular Risk Factors and Estimated 10-Year Risk of Fatal Cardiovascular Events Using Various Equations in Greeks With Metabolic Syndrome. <i>Angiology</i> , 2010, 61, 49-57.	1.8	14
495	Should raising high-density lipoprotein cholesterol be a matter of debate?. <i>Journal of Cardiovascular Medicine</i> , 2012, 13, 254-259.	1.5	14
496	Clinical benefits of ezetimibe use: is absence of proof, proof of absence?. <i>Expert Opinion on Pharmacotherapy</i> , 2012, 13, 1985-1988.	1.9	14
497	Uric acid, chronic kidney disease and type 2 diabetes: A cluster of vascular risk factors. <i>Journal of Diabetes and Its Complications</i> , 2014, 28, 122-123.	2.5	14
498	Strategies to overcome statin intolerance. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2015, 11, 851-855.	3.4	14
499	Inverse association between serum antioxidant levels and inflammatory markers is moderated by adiposity: a report based on a large representative population sample of American adults. <i>British Journal of Nutrition</i> , 2018, 120, 1272-1278.	2.4	14
500	Cardiovascular safety of oncologic agents: A double-edged sword even in the era of targeted therapies “ part 1. <i>Expert Opinion on Drug Safety</i> , 2018, 17, 875-892.	2.5	14
501	Association of Empirical Dietary Atherogenic Indices with All-Cause and Cause-Specific Mortality in a Multi-Ethnic Adult Population of the United States. <i>Nutrients</i> , 2019, 11, 2323.	4.2	14
502	Rationale for screening selected patients for asymptomatic carotid artery stenosis. <i>Current Medical Research and Opinion</i> , 2020, 36, 361-365.	2.0	14
503	Non-coronary atherosclerotic cardiovascular disease in patients with familial hypercholesterolaemia. <i>Current Medical Research and Opinion</i> , 2020, 36, 731-740.	2.0	14
504	Inflammatory Markers Associated With Diabetes Mellitus “ Old and New Players. <i>Current Pharmaceutical Design</i> , 2021, 27, 3020-3035.	1.9	14

#	ARTICLE	IF	CITATIONS
505	Metabolic Syndrome: Clinical Features Leading to Therapeutic Strategies. <i>Vascular Disease Prevention</i> , 2004, 1, 243-253.	0.2	14
506	Ageing Mechanisms and Associated Lipid Changes. <i>Current Vascular Pharmacology</i> , 2013, 12, 682-689.	1.5	14
507	Effects of Improving Glycemic Control with Insulin on Leptin, Adiponectin, Ghrelin and Neuropeptidey Levels in Patients with Type 2 Diabetes Mellitus: a Pilot Study. <i>Open Cardiovascular Medicine Journal</i> , 2011, 5, 136-147.	0.4	14
508	Optimal Management of Asymptomatic Carotid Stenosis in 2021: The Jury is Still Out. An International, Multispecialty, Expert Review and Position Statement. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2022, 31, 106182.	1.7	14
509	A thesis for all seasons. <i>Nature</i> , 1991, 353, 789-790.	36.3	13
510	Endothelin and erectile dysfunction: a target for pharmacological intervention?. <i>Expert Opinion on Investigational Drugs</i> , 1998, 7, 1759-1767.	4.2	13
511	Possible Role of Endothelin-1 in the Rabbit Urinary Bladder Hyperplasia Secondary to Partial Bladder Outlet Obstruction. <i>Scandinavian Journal of Urology and Nephrology</i> , 2000, 34, 15-20.	1.4	13
512	Gene therapy and erectile dysfunction: the current status. <i>Asian Journal of Andrology</i> , 2007, 9, 8-15.	1.9	13
513	Antisense technology for the prevention or the treatment of cardiovascular disease: The next blockbuster?. <i>Expert Opinion on Investigational Drugs</i> , 2008, 17, 969-972.	4.2	13
514	Does Gender Influence the Patency of Infrainguinal Bypass Grafts?. <i>Angiology</i> , 2008, 59, 278-282.	1.8	13
515	The Effect of Tirofiban on Fibrinogen/Agonist-Induced Platelet Shape Change and Aggregation. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2008, 14, 295-302.	1.7	13
516	Editorial: [Statins and Cardiovascular Events in Patients with End-Stage Renal Disease on Hemodialysis. The AURORA Results Suggest the Need for Earlier Intervention]. <i>Current Vascular Pharmacology</i> , 2009, 7, 264-266.	1.5	13
517	The Effect of Antihypertensive Agents on Insulin Sensitivity, Lipids and Haemostasis. <i>Current Vascular Pharmacology</i> , 2010, 8, 792-803.	1.5	13
518	Incidence of end-stage renal disease in the elderly: a steadily rising global socioeconomic epidemic. <i>International Urology and Nephrology</i> , 2010, 42, 523-525.	1.5	13
519	Ezetimibe and low density lipoprotein subfractions: an ongoing debate. <i>Current Medical Research and Opinion</i> , 2011, 27, 693-695.	2.0	13
520	Editorial Assessing renal function “ searching for the perfect marker continues!. <i>Archives of Medical Science</i> , 2011, 4, 565-567.	0.9	13
521	Prevalence, Predictors, and Impact of Low High-Density Lipoprotein Cholesterol on in-Hospital Outcomes Among Acute Coronary Syndrome Patients in the Middle East. <i>Open Cardiovascular Medicine Journal</i> , 2011, 5, 203-209.	0.4	13
522	The effect of biological age on the metabolic responsiveness of mice fed a high-fat diet. <i>Laboratory Animals</i> , 2013, 47, 241-244.	1.1	13

#	ARTICLE	IF	CITATIONS
523	Statins and Infrainguinal Vascular Bypass Procedures. <i>Current Vascular Pharmacology</i> , 2013, 11, 51-57.	1.5	13
524	Adiposity mediates the association between whole grain consumption, glucose homeostasis and insulin resistance: findings from the US NHANES. <i>Lipids in Health and Disease</i> , 2018, 17, 219.	3.1	13
525	A higher ratio of refined grain to whole grain is associated with a greater likelihood of chronic kidney disease: a population-based study. <i>British Journal of Nutrition</i> , 2019, 121, 1294-1302.	2.4	13
526	Diabetes Mellitus and Noncardiac Atherosclerotic Vascular Disease—Pathogenesis and Pharmacological Treatment Options. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2021, 26, 25-39.	2.2	13
527	The association between serum uric acid levels and 10-year cardiovascular disease incidence: results from the ATTICA prospective study. <i>Reviews in Cardiovascular Medicine</i> , 2021, 22, 991.	1.4	13
528	Erythropoietin update 2011. <i>Medical Science Monitor</i> , 2011, 17, RA240-RA247.	1.2	13
529	Management of a Patient With a Null Low-Density Lipoprotein Receptor Mutation. <i>Angiology</i> , 2007, 57, 729-732.	1.8	12
530	Established and emerging vascular risk factors and the development of aortic stenosis: an opportunity for prevention?. <i>Expert Opinion on Therapeutic Targets</i> , 2008, 12, 809-820.	3.4	12
531	Aortic stiffness in diabetes mellitus — association with glutamine and heat shock protein 70 expression: a pilot study based on an experimental rodent model. <i>Expert Opinion on Therapeutic Targets</i> , 2009, 13, 267-274.	3.4	12
532	Colesevelam improves glycemic control and lipid management in inadequately controlled type 2 diabetes mellitus. <i>Nature Clinical Practice Endocrinology and Metabolism</i> , 2009, 5, 16-17.	1.5	12
533	ESVS Guidelines: Section B - Diagnosis and Investigation of Patients with Carotid Stenosis. <i>Current Vascular Pharmacology</i> , 2010, 8, 682-691.	1.5	12
534	The Estrogenic Burden on Vascular Risk in Male-to-Female Transsexuals. <i>Current Pharmaceutical Design</i> , 2010, 16, 3815-3822.	1.9	12
535	Prevalence of low high-density lipoprotein cholesterol (HDL-C) as a marker of residual cardiovascular risk among acute coronary syndrome patients from Oman. <i>Current Medical Research and Opinion</i> , 2011, 27, 879-885.	2.0	12
536	Dyslipidemia Induced by Drugs Used for the Prevention and Treatment of Vascular Diseases. <i>Open Cardiovascular Medicine Journal</i> , 2011, 5, 85-89.	0.4	12
537	Ideal lipid profile and genes for an extended life span. <i>Current Opinion in Cardiology</i> , 2011, 26, 348-355.	1.9	12
538	Perioperative/Periprocedural Effects of Statin Treatment for Patients Undergoing Vascular Surgery or Endovascular Procedures: An Update. <i>Current Vascular Pharmacology</i> , 2012, 11, 112-120.	1.5	12
539	All-cause mortality and estimated renal function in type 2 diabetes mellitus outpatients: Is there a relationship with the equation used?. <i>Diabetes and Vascular Disease Research</i> , 2015, 12, 46-52.	2.0	12
540	Ideal cardiovascular health associated with fatty liver: Results from a multi-ethnic survey. <i>Atherosclerosis</i> , 2019, 284, 129-135.	0.9	12

#	ARTICLE	IF	CITATIONS
541	Cholesterol, carotid artery disease and stroke: what the vascular specialist needs to know. <i>Annals of Translational Medicine</i> , 2020, 8, 1265-1265.	1.7	12
542	Weight-centric pharmacological management of type 2 diabetes mellitus – An essential component of cardiovascular disease prevention. <i>Journal of Diabetes and Its Complications</i> , 2020, 34, 107619.	2.5	12
543	Narrative review on clinical considerations for patients with diabetes and COVID-19: More questions than answers. <i>International Journal of Clinical Practice</i> , 2021, 75, e14833.	1.8	12
544	Gender and Socio-economic Differences in Daily Smoking and Smoking Cessation Among Adult Residents in a Greek Rural Area. <i>Open Cardiovascular Medicine Journal</i> , 2012, 6, 15-21.	0.4	12
545	Design and rationale of a nationwide screening analysis from the LIPIDOGram2015 and LIPIDOGEn2015 studies. <i>Archives of Medical Science</i> , 2020, 18, 604-616.	0.9	12
546	Do we need a statin-nicotinic acid-aspirin mini-polypill to treat combined hyperlipidaemia?. <i>Expert Opinion on Pharmacotherapy</i> , 2007, 8, 2267-2277.	1.9	11
547	Atenolol: Differences in Mode of Action Compared with other Antihypertensives. An Opportunity to Identify Features that Influence Outcome?. <i>Current Pharmaceutical Design</i> , 2007, 13, 229-239.	1.9	11
548	Smoking, Abdominal Aortic Aneurysms, and Ischemic Heart Disease: Is There a Link?. <i>Angiology</i> , 2008, 59, 664-666.	1.8	11
549	Carotid Artery Stenting May Be Losing the Battle against Carotid Endarterectomy for the Management of Symptomatic Carotid Artery Stenosis, But the Jury Is Still Out. <i>Vascular</i> , 2009, 17, 183-189.	0.9	11
550	Statins and venous thromboembolism: a novel effect of statins?. <i>Current Medical Research and Opinion</i> , 2009, 25, 1807-1809.	2.0	11
551	Preventing Type 2 Diabetes Mellitus: Room for Residual Risk Reduction After Lifestyle Changes?. <i>Current Pharmaceutical Design</i> , 2010, 16, 3839-3847.	1.9	11
552	Undertreatment of hypercholesterolemia. <i>Current Medical Research and Opinion</i> , 2010, 26, 439-443.	2.0	11
553	Local Versus General Anesthesia for Carotid Endarterectomy. <i>Angiology</i> , 2012, 63, 405-408.	1.8	11
554	Water Soluble Vitamin E Administration in Wistar Rats with Non-alcoholic Fatty Liver Disease. <i>Open Cardiovascular Medicine Journal</i> , 2012, 6, 88-97.	0.4	11
555	Editorial [Reducing Cardiovascular Risk: Is Low-Density Lipoprotein-Cholesterol (LDL-C) Lowering Enough?]. <i>Current Vascular Pharmacology</i> , 2012, 10, 173-177.	1.5	11
556	Statins and nonalcoholic fatty liver disease: a bright future?. <i>Expert Opinion on Investigational Drugs</i> , 2013, 22, 1089-1093.	4.2	11
557	Metabolic Syndrome and Abnormal Peri-Organ or Intra-Organ Fat (APIFat) Deposition in Chronic Obstructive Pulmonary Disease: An Overview. <i>Metabolites</i> , 2020, 10, 465.	3.0	11
558	Commentary: From mice to men: In search for dietary interventions to form the background on which pharmacotherapy for non-alcoholic fatty liver disease should be based. <i>Metabolism: Clinical and Experimental</i> , 2020, 109, 154305.	3.7	11

#	ARTICLE	IF	CITATIONS
559	Aliskiren, a Direct Renin Inhibitor, in Clinical Practice: A New Approach in the Treatment of Hypertension. <i>Current Vascular Pharmacology</i> , 2010, 8, 344-362.	1.5	11
560	Involvement of Signaling Molecules on Na ⁺ /H ⁺ Exchanger-1 Activity in Human Monocytes. <i>Open Cardiovascular Medicine Journal</i> , 2010, 4, 181-188.	0.4	11
561	Rectus Sheath Hematoma: A Simplified Emergency Surgical Approach. <i>Open Cardiovascular Medicine Journal</i> , 2011, 5, 4-5.	0.4	11
562	The Differences in the Prevalence of Cardiovascular Disease, Its Risk Factors, and Achievement of Therapeutic Goals among Urban and Rural Primary Care Patients in Poland: Results from the LIPIDOGRAM 2015 Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 5656.	2.6	11
563	More on PROSPER. <i>Lancet, The</i> , 2003, 361, 1135-1136.	12.2	10
564	Lipid Lowering Therapy in the Elderly: Is there a Benefit?. <i>Current Pharmaceutical Design</i> , 2006, 12, 3945-60.	1.9	10
565	The Relationship Between Circulating Fibrinogen and Lipoprotein (a) Levels in Patients With Primary Dyslipidemia. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2007, 13, 35-42.	1.7	10
566	The importance of treating multiple cardiometabolic risk factors in patients with Type 2 diabetes. <i>Expert Opinion on Pharmacotherapy</i> , 2007, 8, 3009-3020.	1.9	10
567	Shape of the Nations survey and attitudes to cardiometabolic risk. <i>Current Medical Research and Opinion</i> , 2007, 23, 25-28.	2.0	10
568	Lipid abnormalities and cardiovascular risk in the elderly. <i>Current Medical Research and Opinion</i> , 2008, 24, 653-657.	2.0	10
569	Statins and Heart Failure. <i>Angiology</i> , 2008, 59, 58S-61S.	1.8	10
570	Soluble but Not Platelet P-selectin Correlates With Spontaneous Platelet Aggregation: A Pilot Study. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2008, 14, 227-233.	1.7	10
571	The Role of Trimetazidine After Acute Myocardial Infarction. <i>Current Vascular Pharmacology</i> , 2008, 6, 282-291.	1.5	10
572	Lipid Profile, Low-Density Lipoprotein Oxidation and Ceruloplasmin in the Progeny of Families with a Positive History of Cardiovascular Diseases and/or Hyperlipidemia. <i>Angiology</i> , 2009, 60, 455-461.	1.8	10
573	Gender Differences in the Treatment of Ischemic Heart Disease. <i>Current Pharmaceutical Design</i> , 2011, 17, 1059-1069.	1.9	10
574	Statin therapy and new-onset diabetes: an attempt at recommendations. <i>Expert Review of Endocrinology and Metabolism</i> , 2013, 8, 213-216.	2.4	10
575	Short-, mid-, and long-term benefits of peri-procedural high-intensity statin administration in patients undergoing percutaneous coronary intervention. <i>Current Medical Research and Opinion</i> , 2015, 31, 191-195.	2.0	10
576	Editorial: Resolution of Non-Alcoholic-Steatohepatitis. More than One Drug Needed?. <i>Current Vascular Pharmacology</i> , 2016, 14, 313-315.	1.5	10

#	ARTICLE	IF	CITATIONS
577	Statins and non-alcoholic steatohepatitis. <i>Journal of Hepatology</i> , 2016, 64, 241-242.	4.0	10
578	Non-alcoholic fatty liver disease and cardiovascular risk: an update. <i>Expert Review of Gastroenterology and Hepatology</i> , 2018, 12, 1175-1177.	3.1	10
579	Impact of serum 25-hydroxyvitamin D 25(OH) on telomere attrition: A Mendelian Randomization study. <i>Clinical Nutrition</i> , 2020, 39, 2730-2733.	5.2	10
580	Potato consumption is associated with total and cause-specific mortality: a population-based cohort study and pooling of prospective studies with 98,569 participants. <i>Archives of Medical Science</i> , 2020, 16, 260-272.	0.9	10
581	More Good News on Statins and COVID-19. <i>American Journal of Cardiology</i> , 2021, 138, 127-128.	1.6	10
582	Serum anti-inflammatory and inflammatory markers have no causal impact on telomere length: a Mendelian randomization study. <i>Archives of Medical Science</i> , 2021, 17, 739-751.	0.9	10
583	Lipoprotein (a) as a treatment target for cardiovascular disease prevention and related therapeutic strategies: a critical overview. <i>European Journal of Preventive Cardiology</i> , 2022, 29, 739-755.	1.9	10
584	Statin Treatment, Carotid Atherosclerotic Plaque Macrophage Infiltration and Circulating Inflammatory Markers. <i>Open Cardiovascular Medicine Journal</i> , 2008, 2, 110-114.	0.4	10
585	Update on Cilostazol: A Critical Review of Its Antithrombotic and Cardiovascular Actions and Its Clinical Applications. <i>Journal of Clinical Pharmacology</i> , 2022, 62, 320-358.	2.1	10
586	Achieving Vascular Risk Factor Targets: A Survey of a London General Practice. <i>Angiology</i> , 2008, 59, 36-46.	1.8	9
587	Statins and Heart Failure. <i>Journal of the American College of Cardiology</i> , 2010, 55, 1644-1645.	5.6	9
588	Is the Risk for Cardiovascular Disease Increased in all Phenotypes of the Polycystic Ovary Syndrome?. <i>Angiology</i> , 2011, 62, 285-290.	1.8	9
589	State of the art papers Is there an additional benefit from coronary revascularization in diabetic patients with acute coronary syndromes or stable angina who are already on optimal medical treatment?. <i>Archives of Medical Science</i> , 2011, 6, 1067-1075.	0.9	9
590	Mechanisms Linking Nonalcoholic Fatty Liver Disease with Coronary Artery Disease. <i>Digestive Diseases and Sciences</i> , 2012, 57, 1109-1109.	2.5	9
591	Summarizing the FIELD study: lessons from a 'negative' trial. <i>Expert Opinion on Pharmacotherapy</i> , 2013, 14, 2601-2610.	1.9	9
592	The 2013 American College of Cardiology/American Heart Association guidelines for the treatment of dyslipidemia: mind the gaps!. <i>Current Medical Research and Opinion</i> , 2014, 30, 1701-1705.	2.0	9
593	In reply "Coenzyme Q10 and Statin-Induced Myopathy. <i>Mayo Clinic Proceedings</i> , 2015, 90, 420-421.	2.9	9
594	Reduced Serum Vitamin D Levels Are Associated with Insulin Resistance in Patients with Obstructive Sleep Apnea Syndrome. <i>Medicina (Lithuania)</i> , 2019, 55, 174.	2.1	9

#	ARTICLE	IF	CITATIONS
595	Apolipoprotein B/Apolipoprotein A-I Ratio Is a Better Predictor of Cancer Mortality Compared with C-Reactive Protein: Results from Two Multi-Ethnic US Populations. <i>Journal of Clinical Medicine</i> , 2020, 9, 170.	2.6	9
596	Hypolipidaemic Drug Treatment: Yesterday is Not Gone Yet, Today is Challenging and Tomorrow is Coming Soon; let us Combine them all. <i>Current Pharmaceutical Design</i> , 2014, 20, 6350-6357.	1.9	9
597	Statins and Type 2 Diabetes Mellitus: An Update After 1 Year. <i>Current Pharmaceutical Design</i> , 2016, 22, 2723-2725.	1.9	9
598	Epicardial fat: a novel marker of subclinical atherosclerosis in clinical practice?. <i>Anatolian Journal of Cardiology</i> , 2017, 17, 64-65.	0.8	9
599	Decreased urinary bladder apoptosis in a rabbit model of diabetes mellitus. <i>Urological Research</i> , 2002, 30, 79-83.	1.5	8
600	Increased platelet purinergic sensitivity in peripheral arterial disease – A pilot study. <i>Platelets</i> , 2005, 16, 261-267.	2.1	8
601	Cholesteryl ester transfer protein inhibition and HDL increase: has the dream ended?. <i>Expert Opinion on Investigational Drugs</i> , 2008, 17, 445-449.	4.2	8
602	JUPITER: major implications for vascular risk assessment. <i>Current Medical Research and Opinion</i> , 2009, 25, 133-137.	2.0	8
603	Proposing a ‘Lipemic Index’; As a Nutritional and Research Tool. <i>Current Vascular Pharmacology</i> , 2011, 9, 313-317.	1.5	8
604	Postprandial Lipemia in Children and Adolescents. <i>Current Vascular Pharmacology</i> , 2011, 9, 318-320.	1.5	8
605	Relation of Improvement in Glomerular Filtration Rate With Atorvastatin to Reductions in Heart Failure Morbidity. <i>American Journal of Cardiology</i> , 2012, 110, 763.	1.6	8
606	Lipoprotein alterations and reduced growth hormone secretion: relationships with obesity and cardiovascular risk ^{>1</sup>. <i>Clinical Endocrinology</i>, 2012, 76, 177-178.}	2.7	8
607	Statins in Patients With Renal Dysfunction. <i>American Journal of Cardiology</i> , 2012, 109, 1537.	1.6	8
608	Editorial (Diabetes, Obesity and Vascular Disease - An Update). <i>Current Pharmaceutical Design</i> , 2013, 19, 4900-4903.	1.9	8
609	Risk of illness, hospitalization and death in a cohort of blood donors in Italy. <i>Current Medical Research and Opinion</i> , 2014, 30, 1803-1812.	2.0	8
610	Subclinical Cushing's syndrome and cardiovascular disease. <i>Lancet Diabetes and Endocrinology</i> , the, 2014, 2, 361.	11.0	8
611	Hyperuricaemia in Cardiovascular Diseases: A Passive or an Active Player?. <i>Medical Principles and Practice</i> , 2015, 24, 269-270.	2.4	8
612	Impact of comorbidity on outcome in kidney transplant recipients: a retrospective study in Italy. <i>Internal and Emergency Medicine</i> , 2016, 11, 825-832.	2.3	8

#	ARTICLE	IF	CITATIONS
613	High incidence of metabolic syndrome further increases cardiovascular risk in patients with type 2 diabetes. Implications for everyday practice. <i>Journal of Diabetes and Its Complications</i> , 2016, 30, 9-11.	2.5	8
614	Cardiovascular safety of oncologic agents: a double-edged sword even in the era of targeted therapies – Part 2. <i>Expert Opinion on Drug Safety</i> , 2018, 17, 893-915.	2.5	8
615	Left atrial volume: An independent predictor of cardiovascular outcomes. <i>International Journal of Cardiology</i> , 2018, 265, 234-235.	1.7	8
616	Effect of Dietary Insulinemia on All-Cause and Cause-Specific Mortality: Results From a Cohort Study. <i>Journal of the American College of Nutrition</i> , 2020, 39, 407-413.	3.1	8
617	Hydrochlorothiazide vs. Chlorthalidone as the Optimal Diuretic for the Management of Hypertension. <i>Current Pharmaceutical Design</i> , 2013, 19, 3766-3772.	1.9	8
618	Cholesteryl Ester Transfer Protein Gene and Effectiveness of Lipid Lowering of Atorvastatin. <i>Open Cardiovascular Medicine Journal</i> , 2010, 4, 297-301.	0.4	8
619	Ezetimibe/simvastatin single tablet versus rosuvastatin in patients with hypercholesterolemia. <i>Current Medical Research and Opinion</i> , 2006, 22, 2037-2039.	2.0	7
620	Statins and Regression of Coronary Atherosclerosis. <i>JAMA - Journal of the American Medical Association</i> , 2007, 297, 2197.	7.1	7
621	Serotonin Induces a Biphasic Response in Rabbit Cavernosal Smooth Muscle: Relevance to the Erectile Process. <i>Urologia Internationalis</i> , 2007, 79, 255-261.	1.4	7
622	Editorial [Hot Topic: Experimental Models for the Study of Drugs Used to Prevent and Treat Vascular Diseases (Executive Editors: C.S. Thompson, D.P. Mikhailidis and K.I. Paraskevas)]. <i>Current Pharmaceutical Design</i> , 2008, 14, 306-308.	1.9	7
623	CORONA, Statins, and Heart Failure: Who Lost the Crown?. <i>Angiology</i> , 2008, 59, 5-8.	1.8	7
624	Editorial [Angiogenesis: A Promising Treatment Option for Peripheral Arterial Disease]. <i>Current Vascular Pharmacology</i> , 2008, 6, 78-80.	1.5	7
625	Acute Limb Ischemia Caused by Femoral Arterial Line Induces Remote Liver Injury in a Rabbit Model of Liver Ischemia/Reperfusion Injury. <i>Angiology</i> , 2009, 60, 554-561.	1.8	7
626	Statin-fibrate combination for mixed dyslipidaemia: a limited option?. <i>Current Medical Research and Opinion</i> , 2010, 26, 2137-2140.	2.0	7
627	Statins may not prevent structural valve degeneration of aortic bioprosthetic valves, but should probably be prescribed to patients undergoing heart valve surgery nonetheless. <i>Interactive Cardiovascular and Thoracic Surgery</i> , 2010, 11, 302-302.	1.2	7
628	To switch (statins) or not to switch? That is the question. <i>Expert Opinion on Pharmacotherapy</i> , 2010, 11, 2943-2946.	1.9	7
629	Correlation of the severity of diabetic retinopathy and the heart muscle perfusion in patients with type 2 diabetes. <i>Journal of Diabetes and Its Complications</i> , 2011, 25, 253-257.	2.5	7
630	Screening for peripheral artery disease in dialysis patients: an opportunity for early disease detection and timely initiation of appropriate therapeutic measures. <i>International Urology and Nephrology</i> , 2011, 43, 143-145.	1.5	7

#	ARTICLE	IF	CITATIONS
631	Glycated hemoglobin A1c(HbA1c) and diabetes: a new era?. <i>Current Medical Research and Opinion</i> , 2011, 27, 7-11.	2.0	7
632	Passive Smoking: The Democratic Right of Nonsmokers to Survive. <i>Angiology</i> , 2011, 62, 520-522.	1.8	7
633	Effect of Antiplatelet Agents, Statins, and Other Drugs on Vascular Access Patency Rates. <i>Angiology</i> , 2012, 63, 5-8.	1.8	7
634	Statins and Venous Thromboembolism. <i>Angiology</i> , 2013, 64, 489-491.	1.8	7
635	Editorial: Statin Potency, LDL Receptors and New Onset Diabetes. <i>Current Vascular Pharmacology</i> , 2014, 12, 739-740.	1.5	7
636	Letter to the Editor Dysfunctional high-density lipoprotein: not only quantity but first of all quality?. <i>Archives of Medical Science</i> , 2015, 1, 230-231.	0.9	7
637	The impact of metabolic syndrome and its components on perioperative outcomes after elective laparotomy - A prospective observational study. <i>American Journal of Surgery</i> , 2017, 214, 831-837.	1.7	7
638	More on carotid atherosclerosis and ezetimibe. <i>International Angiology</i> , 2017, 36, 580-581.	0.9	7
639	Carotid Bifurcation Geometry as Assessed by Ultrasound is Associated with Early Carotid Atherosclerosis. <i>Annals of Vascular Surgery</i> , 2018, 51, 207-216.	1.0	7
640	Dyslipidaemia in the elderly: to treat or not to treat?. <i>Expert Review of Clinical Pharmacology</i> , 2018, 11, 259-278.	3.2	7
641	Appropriate Patient Selection for Carotid Revascularization Procedures is Urgently Needed. <i>Angiology</i> , 2018, 69, 12-16.	1.8	7
642	Management of patients with type 2 diabetes mellitus and acute coronary syndrome: Better be safe than sorry!. <i>Journal of Diabetes and Its Complications</i> , 2019, 33, 465-467.	2.5	7
643	Excessive orthotopic fat accumulation: Links with cardiometabolic diseases and potential drug treatment. <i>Journal of Cellular Physiology</i> , 2020, 235, 6321-6322.	4.2	7
644	Comparison of Recent Practice Guidelines for the Management of Patients With Asymptomatic Carotid Stenosis. <i>Angiology</i> , 2022, 73, 903-910.	1.8	7
645	Muscarinic stimulation of prostanoid synthesis by the isolated rat trachea: calcium dependency and effect of cortisol and cigarette smoke. <i>European Journal of Pharmacology</i> , 1989, 160, 107-115.	3.6	6
646	β -Glutamyltransferase and Vascular Disease. <i>Clinical Chemistry</i> , 2003, 49, 522-523.	3.5	6
647	Clopidogrel and vascular disease prevention. <i>Current Medical Research and Opinion</i> , 2004, 20, 1835-1838.	2.0	6
648	Mean platelet volume in patients with type 2 diabetes mellitus. <i>Platelets</i> , 2005, 16, 219-220.	2.1	6

#	ARTICLE	IF	CITATIONS
649	Primary and secondary coronary heart disease prevention using statins: is targeting Adam or Eve equally effective?. <i>Expert Opinion on Pharmacotherapy</i> , 2008, 9, 1437-1440.	1.9	6
650	Editorial [Has the Time Come for a New Definition of Microalbuminuria?]. <i>Current Vascular Pharmacology</i> , 2008, 6, 81-83.	1.5	6
651	Anaesthetic techniques for carotid surgery. <i>Lancet, The</i> , 2009, 373, 807.	12.2	6
652	Statin use in patients with chronic kidney disease stages 2-4: targeting beyond improved mortality rates. <i>International Urology and Nephrology</i> , 2010, 42, 711-713.	1.5	6
653	Relationships of osteoprotegerin with albuminuria and asymmetric dimethylarginine in essential hypertension: integrating vascular dysfunction. <i>Expert Opinion on Therapeutic Targets</i> , 2011, 15, 1347-1353.	3.4	6
654	A New Rapid Method to Measure Human Platelet Cholesterol. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2011, 17, 578-584.	1.7	6
655	Peripheral Arterial Disease and HIV-Positive Patients. <i>Angiology</i> , 2011, 62, 7-9.	1.8	6
656	Smoking and non-alcoholic steatohepatitis (NASH): The GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) trial. <i>Journal of Hepatology</i> , 2012, 57, 476.	4.0	6
657	State of the art paper The role of G protein coupled receptor kinases in neurocardiovascular pathophysiology. <i>Archives of Medical Science</i> , 2012, 6, 970-977.	0.9	6
658	Mean platelet volume in patients undergoing percutaneous coronary intervention. <i>Platelets</i> , 2015, 26, 269-270.	2.1	6
659	Platelets and diabetes: A complex association. <i>Platelets</i> , 2015, 26, 267-268.	2.1	6
660	Statins and non-alcoholic steatohepatitis. <i>Metabolism: Clinical and Experimental</i> , 2017, 66, e1-e2.	3.7	6
661	Editorial: Lipoprotein (a), More than Just Cholesterol?. <i>Current Medicinal Chemistry</i> , 2017, 24, 952-956.	2.5	6
662	Iron absorption, bone marrow fat and hematopoiesis in heart failure: Additional mechanisms of action for sodium-glucose co-transporter 2 inhibitors (SGLT2i)?. <i>Journal of Diabetes and Its Complications</i> , 2019, 33, 107408.	2.5	6
663	Contrast-induced Nephropathy in Non-cardiac Vascular Procedures, A Narrative Review: Part 1. <i>Current Vascular Pharmacology</i> , 2022, 20, 3-15.	1.5	6
664	The Link Between Human and Transgenic Animal Studies Involving Postprandial Hypertriglyceridemia and CETP Gene Polymorphisms. <i>Open Cardiovascular Medicine Journal</i> , 2009, 3, 48-50.	0.4	6
665	Weekend Versus Weekday, Morning Versus Evening Admission in Relationship to Mortality in Acute Coronary Syndrome Patients in 6 Middle Eastern Countries: Results from Gulf Race 2 Registry. <i>Open Cardiovascular Medicine Journal</i> , 2012, 6, 106-112.	0.4	6
666	Adverse impact of egg consumption on fatty liver is partially explained by cardiometabolic risk factors: A population-based study. <i>Clinical Nutrition</i> , 2020, 39, 3730-3735.	5.2	6

#	ARTICLE	IF	CITATIONS
667	Alice through the Looking-glass: Can We Improve Peer Review?. International Journal of Lower Extremity Wounds, 2022, , 153473462210847.	1.2	6
668	Statins and diabetes mellitus progression: a fly in the ointment?. Nature Reviews Endocrinology, 2022, 18, 137-138.	9.7	6
669	Differential Alterations of Spontaneous and Stimulated $^{45}\text{Ca}^{2+}$ Uptake by Platelets from Patients with Type I and Type II Diabetes Mellitus. Journal of Diabetes and Its Complications, 1999, 13, 271-276.	2.5	5
670	The Molecular Basis of Penile Erection. Current Medical Research and Opinion, 2000, 16, s21-s30.	2.0	5
671	Sildenafil: a Urologist's View. Current Medical Research and Opinion, 2000, 16, s48-s58.	2.0	5
672	Platelet Activation in Bypass Surgery for Critical Limb Ischemia. Vascular and Endovascular Surgery, 2007, 41, 322-329.	0.7	5
673	Obesity and postoperative atrial fibrillation. Is there no connection?. American Heart Journal, 2008, 156, e5.	3.1	5
674	Preventing macrovascular complications of diabetes: where do we stand with glycemic control?. Expert Opinion on Investigational Drugs, 2008, 17, 1777-1779.	4.2	5
675	Kidney Function and Estimated Vascular Risk in Patients with Primary Dyslipidemia. Open Cardiovascular Medicine Journal, 2009, 3, 57-68.	0.4	5
676	Irradiation-Induced Carotid Artery Stenosis: A Preventable Complication of Neck Radiotherapy?. Angiology, 2009, 60, 273-275.	1.8	5
677	Is High-sensitivity C-reactive Protein Associated with Subclinical Peripheral Atherosclerosis?. Angiology, 2009, 60, 8-11.	1.8	5
678	Percutaneous Coronary Interventions Affect Concentrations of Interleukin 6 and Its Soluble Receptors in Coronary Sinus Blood in Patients with Stable Angina. Angiology, 2009, 60, 322-328.	1.8	5
679	Bilirubin and peripheral arterial disease: 15 years later. Expert Opinion on Therapeutic Targets, 2009, 13, 139-140.	3.4	5
680	Severe, But Not Moderate, Carotid Atherosclerosis May Predict Concomitant Vascular Disease in Other Arterial Beds. Stroke, 2010, 41, e597; author reply e598.	5.0	5
681	Molecular markers and bladder carcinoma: Schistosomal and non-schistosomal. Clinical Biochemistry, 2011, 44, 237-244.	2.0	5
682	The DEFINE study: a bright future for CETP inhibitors?. Expert Opinion on Investigational Drugs, 2011, 20, 311-314.	4.2	5
683	Managing the combination of non-alcoholic fatty liver disease and metabolic syndrome. Expert Opinion on Pharmacotherapy, 2012, 13, 287-288.	1.9	5
684	Therapeutic options for statin-intolerant patients. Current Medical Research and Opinion, 2012, 28, 345-349.	2.0	5

#	ARTICLE	IF	CITATIONS
685	Effect of Atorvastatin Monotherapy and Low-Dose Atorvastatin/Ezetimibe Combination on Fasting and Postprandial Triglycerides in Combined Hyperlipidemia. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2012, 17, 427-427.	2.2	5
686	Ezetimibe â€“ a new approach in hypercholesterolemia management. <i>Pharmacological Reports</i> , 2012, 64, 997-998.	3.4	5
687	Targeting cardiovascular risk: the impact of age, gender and compliance to treatment. <i>Current Medical Research and Opinion</i> , 2012, 28, 1415-1419.	2.0	5
688	Should we consider ezetimibe to reach even lower LDL-C targets?. <i>Current Medical Research and Opinion</i> , 2015, 31, 459-460.	2.0	5
689	Changing Cities, Changing Culture. <i>Advances in Developing Human Resources</i> , 2015, 17, 460-472.	3.9	5
690	Does bilirubin protect against developing diabetes mellitus?. <i>Journal of Diabetes and Its Complications</i> , 2016, 30, 728-737.	2.5	5
691	Pioglitazone in patients with insulin resistance after ischemic stroke or transient ischemic attack: A comment on the IRIS trial. <i>Journal of Diabetes and Its Complications</i> , 2017, 31, 1-3.	2.5	5
692	Lipids: a personal view of the past decade. <i>Hormones</i> , 2018, 17, 461-478.	2.1	5
693	The Association Between Abdominal Aortic Aneurysms With Cardiovascular and Noncardiovascular Diseases. <i>Angiology</i> , 2019, 70, 8-11.	1.8	5
694	Endocan and Erectile Dysfunction. <i>American Journal of Men's Health</i> , 2019, 13, 155798831989388.	1.6	5
695	Low-carbohydrate diet: forget restriction, replace with balance!. <i>European Heart Journal</i> , 2020, 41, 1058-1058.	2.4	5
696	microRNAâ€“184 is induced by storeâ€“operated calcium entry and regulates early keratinocyte differentiation. <i>Journal of Cellular Physiology</i> , 2020, 235, 6854-6861.	4.2	5
697	Contrast-induced Nephropathy in Non-cardiac Vascular Procedures, A Narrative Review: Part 2. <i>Current Vascular Pharmacology</i> , 2022, 20, 16-26.	1.5	5
698	Narrative Review of Carotid disease and the kidney. <i>Annals of Translational Medicine</i> , 2021, 9, 1210-1210.	1.7	5
699	Management of patients with asymptomatic carotid stenosis may need to be individualized: a multidisciplinary call for action. Republication of <i>J Stroke</i> 2021;23:202-212. <i>International Angiology</i> , 2021, 40, 487-496.	0.9	5
700	Have We Learnt all from IMPROVE-IT? Part I. Core Results and Subanalyses on the Effects of Ezetimibe Added to Statin Therapy Related to Age, Gender and Selected Chronic Diseases (Kidney Disease, Diabetes) Tj ETQq0.0 0 rgBT5/Overlock		
701	Abnormal Peri-organ-Intra-organ Fat (APIFat) and Rheumatoid Arthritis: An Under-investigated Link for Increased Cardiovascular Risk?. <i>Current Vascular Pharmacology</i> , 2020, 18, 249-253.	1.5	5
702	Increased Fluorodeoxyglucose Uptake Following Endovascular Abdominal Aortic Aneurysm Repair: A Predictor of Endoleak?. <i>Open Cardiovascular Medicine Journal</i> , 2010, 4, 117-119.	0.4	5

#	ARTICLE	IF	CITATIONS
703	Patient with Hypertriglyceridemia, Type 2 Diabetes, and Chronic Kidney Disease Treated with Atorvastatin and Omega-3 Fatty Acid Ethyl Esters. <i>Open Cardiovascular Medicine Journal</i> , 2012, 6, 122-125.	0.4	5
704	Analysis of the impact of sex and age on the variation in the prevalence of antinuclear autoantibodies in Polish population: a nationwide observational, cross-sectional study. <i>Rheumatology International</i> , 2022, 42, 261-271.	3.2	5
705	Relationship between Low-Density Lipoprotein Cholesterol, Lipid Lowering Agents and the Risk of Stroke: A meta-analysis of Observational studies (n=355,591) and Randomized Controlled Trials (n=165,988).. <i>Archives of Medical Science</i> , 2022, , .	0.9	5
706	Effects of statins on specialized pro-resolving mediators: An additional pathway leading to resolution of inflammation. <i>Metabolism: Clinical and Experimental</i> , 2022, 132, 155211.	3.7	5
707	Endothelin-1 and Urinary Bladder Hyperplasia Following Partial Bladder Outlet Obstruction. <i>Journal of Cardiovascular Pharmacology</i> , 2000, 36, S262-S263.	1.9	4
708	New-onset diabetes after transplantation. <i>Lancet, The</i> , 2005, 365, 1766.	12.2	4
709	Mortality after First Myocardial Infarction in Greek Patients: A 4-Year Follow-Up Study. <i>Angiology</i> , 2009, 60, 582-587.	1.8	4
710	Erectile dysfunction: a warning sign of silent vascular disease. <i>International Urology and Nephrology</i> , 2009, 41, 909-911.	1.5	4
711	Chronic Hepatitis C, Insulin Resistance and Vascular Disease. <i>Current Pharmaceutical Design</i> , 2010, 16, 3823-3829.	1.9	4
712	Are Symptomatic Patients Appropriate Candidates For Carotid Artery Stenting? No (at Least Not At) <i>Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5</i>	0.9	4
713	Statins and contrast-induced nephropathy: Issues requiring further investigation. <i>International Journal of Cardiology</i> , 2011, 151, 364.	1.7	4
714	Impact of Statins on Glucose Metabolismâ€”A Matter of Debate. <i>American Journal of Cardiology</i> , 2011, 107, 1866.	1.6	4
715	Why the United States Center for Medicare and Medicaid Services (CMS) should not extend reimbursement indications for carotid artery angioplasty/stenting. <i>Brain and Behavior</i> , 2012, 2, 200-207.	2.3	4
716	Angiotensin II Increases Corpus Cavernosal Contractility and Oxidative Stress in Partial Bladder Outlet Obstructed Rabbits: Relevance to Erectile Dysfunction. <i>Journal of Sexual Medicine</i> , 2013, 10, 1251-1258.	0.8	4
717	Statins: A sine qua non of the management of patients with abdominal aortic aneurysms. <i>International Journal of Cardiology</i> , 2013, 168, 4528.	1.7	4
718	Response to Red Blood Cell Distribution Width Is a Predictor of Readmission in Cardiac Patients. <i>Clinical Cardiology</i> , 2013, 36, 364-365.	2.0	4
719	Regarding â€œProgression of asymptomatic carotid stenosis despite optimal medical therapyâ€• <i>Journal of Vascular Surgery</i> , 2014, 59, 1752-1753.	1.1	4
720	A possible relationship between renal impairment and complications development in type 2 diabetes mellitus: a prospective, observational study in Italy. <i>Journal of Diabetes and Its Complications</i> , 2015, 29, 771-775.	2.5	4

#	ARTICLE	IF	CITATIONS
721	Genetic, epidemiologic and clinical data strongly suggest that fasting or non-fasting triglycerides are independent cardiovascular risk factors. <i>Current Medical Research and Opinion</i> , 2015, 31, 435-438.	2.0	4
722	Effects of tibolone on fibrinogen and antithrombin III: A systematic review and meta-analysis of controlled trials. <i>Pharmacological Research</i> , 2017, 124, 64-73.	7.3	4
723	Lipoprotein Apheresis and Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors in Patients With Heterozygous Familial Hypercholesterolemia: A One Center Study. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2021, 26, 51-58.	2.2	4
724	Have We Learnt all from IMPROVE-IT? Part II. Subanalyses of the Effects of Ezetimibe Added to Statin Therapy on Selected Clinical and Laboratory Outcomes, Cost-Effectiveness, Guidelines, and Clinical Implications. <i>Current Vascular Pharmacology</i> , 2021, 19, 469-486.	1.5	4
725	Acute and long-term antiplatelet therapy. , 2008, 44, 331.		4
726	Reduction of endothelin-1 binding and inhibition of endothelin-1-mediated detrusor contraction by naftidrofuryl. <i>Clinical Science</i> , 2002, 103, 459S-463S.	4.4	3
727	Erectile dysfunction: a need for greater awareness. <i>Perspectives in Public Health</i> , 2004, 124, 214-216.	0.5	3
728	RE: THE PREVALENCE OF HYPERTENSION, HYPERLIPIDEMIA, DIABETES MELLITUS AND DEPRESSION IN MEN WITH ERECTILE DYSFUNCTION. <i>Journal of Urology</i> , 2005, 173, 1050-1050.	3.9	3
729	Effects of Simvastatin Alone Versus Fenofibrate Alone Versus Simvastatin Plus Fenofibrate on Lipoprotein Subparticle Profiles in Patients With Diabetes Mellitus and Mixed Dyslipidemia. <i>American Journal of Cardiology</i> , 2008, 101, 1679-1680.	1.6	3
730	A Comparison of the Aldosterone-Blocking Agents Eplerenone and Spironolactone. <i>Clinical Cardiology</i> , 2009, 32, 230-230.	2.0	3
731	Editorial [Concurrent Blood Pressure, Glycemic and Lipid Control for the Prevention of Vascular Complications of Type II Diabetes Mellitus: A Long Overdue Objective?]. <i>Current Vascular Pharmacology</i> , 2010, 8, 1-4.	1.5	3
732	Interpreting the Carotid Revascularization Endarterectomy Versus Stent Trial (CREST): Additional Trials Are Needed. <i>Vascular</i> , 2010, 18, 247-249.	0.9	3
733	Predictors of Abdominal Aortic Aneurysm (AAA) Growth and AAA Rupture Risk Besides AAA Size: Fact or Fiction?. <i>Angiology</i> , 2010, 61, 321-323.	1.8	3
734	Best medical treatment for a symptomatic carotid artery stenosis. <i>Lancet, The</i> , 2011, 377, 123.	12.2	3
735	Adding Ezetimibe to Statin Treatment: is LDL-C Lowering the Only benefit?. <i>Future Cardiology</i> , 2012, 8, 813-817.	1.1	3
736	Lipids and Non-Cardiac Vascular Disease: A Lecture Overview. <i>Current Vascular Pharmacology</i> , 2012, 10, 743-744.	1.5	3
737	Efficacy and tolerability of once-weekly rosuvastatin in patients with previous statin intolerance. <i>Journal of Clinical Lipidology</i> , 2012, 6, 93.	1.6	3
738	Editorial The clinical benefit of implementing guidelines in cardiovascular disease prevention in real world settings. <i>Archives of Medical Science</i> , 2012, 1, 6-10.	0.9	3

#	ARTICLE	IF	CITATIONS
739	18F-Fluorodeoxyglucose Uptake in Abdominal Aortic Aneurysms: A Useful Biomarker of AAA Rupture Risk. <i>BioMed Research International</i> , 2014, 2014, 1-2.	2.0	3
740	Peripheral artery disease in patients with type 2 diabetes. <i>Journal of Diabetes and Its Complications</i> , 2014, 28, 912.	2.5	3
741	Statins induce regression of carotid artery stenosis: Fact or fiction?. <i>International Journal of Cardiology</i> , 2016, 220, 680.	1.7	3
742	Can the effects of gender, menopause and ageing on lipid levels be differentiated?. <i>Clinical Endocrinology</i> , 2016, 85, 694-695.	2.7	3
743	Critical Issues and Controversies in the Management of Patients With Carotid Artery Stenosis. <i>Angiology</i> , 2016, 67, 405-407.	1.8	3
744	Letter to the editor: Treating nonalcoholic fatty liver disease with statins. Are all statins equal?. <i>American Journal of Physiology - Renal Physiology</i> , 2017, 312, G681-G682.	3.5	3
745	Fetal/Infant Origins of Adult Vascular Disease. <i>Current Vascular Pharmacology</i> , 2020, 18, 418-420.	1.5	3
746	The effect of statins on semen parameters in patients with hypercholesterolemia: A systematic review. <i>Andrology</i> , 2021, 9, 1504-1511.	3.6	3
747	The Rationale for Comparative Studies of Accelerated Atherosclerosis in Rheumatic Diseases. <i>Current Vascular Pharmacology</i> , 2010, 999, 1-13.	1.5	3
748	Low HDL Cholesterol, Smoking and IL-13 R130Q Polymorphism are Associated with Myocardial Infarction in Greek Cypriot Males. A Pilot Study. <i>Open Cardiovascular Medicine Journal</i> , 2008, 2, 52-59.	0.4	3
749	Assessment and Clinical Relevance of Non-Fasting and Postprandial Triglycerides: An Expert Panel Statement. <i>Current Vascular Pharmacology</i> , 2011, 999, 1-13.	1.5	3
750	Measurement of atherosclerosis progression. <i>Lancet, The</i> , 2001, 358, 329-330.	12.2	2
751	Ciprofibrate Versus Gemfibrozil in the Treatment of Mixed Hyperlipidemias: An Open-Label, Multicenter Study. <i>Metabolism: Clinical and Experimental</i> , 2001, 50, 1385-1386.	3.7	2
752	The Effect of Clopidogrel (Plavix) on Platelet Function in Patients with Peripheral Vascular Disease – Comparison with Aspirin. <i>Journal of Cardiac Surgery</i> , 2002, 17, 563-563.	0.8	2
753	Exorcising Ghosts and Unwelcome Guests. <i>Annals of Internal Medicine</i> , 2006, 144, 149.	9.7	2
754	Additional Effects of Statins in Surgical Patients. <i>Annals of Surgery</i> , 2008, 248, 140-141.	4.5	2
755	The Impact of Novel Treatment Modalities on the Therapeutic Approach of Cardiovascular Diseases. <i>Angiology</i> , 2009, 60, 5-7.	1.8	2
756	Aortic Pulse Wave Velocity May Have Prognostic Value Not Just for Hypertension but Also for Abdominal Aortic Aneurysms. <i>Hypertension</i> , 2010, 55, e22; author reply e23.	5.0	2

#	ARTICLE	IF	CITATIONS
757	Endovascular Versus Open Repair of Abdominal Aortic Aneurysms: Interpreting the Landmark United Kingdom EVAR 1 Results. <i>Journal of Endovascular Therapy</i> , 2010, 17, 599-601.	1.7	2
758	Effects of Combined Ezetimibe and Simvastatin Therapy as Compared With Simvastatin Alone in Patients With Type 2 Diabetes: A Prospective Randomized Double-Blind Clinical Trial: Comment on Ruggenenti et al.. <i>Diabetes Care</i> , 2010, 33, e132-e132.	9.3	2
759	Alanine Aminotransferase Is Associated With Metabolic Syndrome Independently of Insulin Resistance. <i>Circulation Journal</i> , 2011, 75, 2027.	1.7	2
760	Impact of Ezetimibe Coadministered With Statins on Cardiovascular Events Following Acute Coronary Syndrome: A 3-Year Population-Based Retrospective Cohort Study in Taiwan. <i>Clinical Therapeutics</i> , 2011, 33, 2091.	2.3	2
761	Current treatment for nonalcoholic fatty liver disease. <i>Expert Opinion on Pharmacotherapy</i> , 2011, 12, 2141-2142.	1.9	2
762	Does Metabolic Syndrome Influence Outcome Following Percutaneous Coronary Intervention?. <i>Angiology</i> , 2011, 62, 437-439.	1.8	2
763	Why the United States Center for Medicare and Medicaid Services should not extend reimbursement indications for carotid artery angioplasty/stenting. <i>Vascular</i> , 2012, 20, 1-7.	0.9	2
764	Hypertriglyceridemia-induced acute pancreatitis: clinical considerations. <i>Clinical Lipidology</i> , 2012, 7, 259-262.	0.4	2
765	Response to Mildly Decreased Glomerular Filtration Rate Is Associated With Poor Coronary Heart Disease Outcome. <i>Clinical Cardiology</i> , 2012, 35, 315-315.	2.0	2
766	Renal dysfunction and all-cause mortality in cardio-renal syndrome: Calculation of glomerular filtration rate is crucial, independent of the equation. <i>International Journal of Cardiology</i> , 2013, 170, e11-e13.	1.7	2
767	Evaluation of the incidence and risk factors for development of fenofibrate-associated nephrotoxicity. <i>Journal of Clinical Lipidology</i> , 2013, 7, 88.	1.6	2
768	Additional Issues on Screening, Prevention, and Treatment of Abdominal Aortic Aneurysms. <i>American Journal of Men's Health</i> , 2013, 7, 472-474.	1.6	2
769	Editorial (Thematic Issue: Novel Data on the Pathogenesis of Atherosclerosis, Treatment Targets, and) Tj ETQq1 1 0.784314 rgBT /Over Design, 2014, 20, 6215-6219.	1.9	2
770	Caloric and fat intake in statin users. <i>Nature Reviews Endocrinology</i> , 2014, 10, 450-451.	9.7	2
771	Editorial (Thematic Issue: Is The Female Heart Exposed To Cardiovascular Disease?). <i>Current Medicinal Chemistry</i> , 2015, 22, 3552-3554.	2.5	2
772	Statins and Niacin: The End of Residual Risk Therapy?. , 2015, , 37-43.		2
773	Comment on Inzucchi et al. Pioglitazone Prevents Diabetes in Patients With Insulin Resistance and Cerebrovascular Disease. <i>Diabetes Care</i> 2016;39:1684-1692. <i>Diabetes Care</i> , 2017, 40, e46-e46.	9.3	2
774	Time for new low density lipoprotein cholesterol (LDL-C) targets?. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 1539-1541.	1.9	2

#	ARTICLE	IF	CITATIONS
775	Statin use in patients with diabetes: one drug, multiple benefits. Expert Review of Cardiovascular Therapy, 2019, 17, 839-840.	1.6	2
776	Half a century and more of PhD theses by published papers. Scientometrics, 2020, 125, 813-816.	3.1	2
777	NAFLD and Statins. Digestive Diseases and Sciences, 2020, 65, 3052-3053.	2.5	2
778	Editorial: The year in hyperlipidaemia. Current Opinion in Cardiology, 2021, 36, 461.	1.9	2
779	Far Wake and Its Relation to Aerodynamic Efficiency. Energies, 2021, 14, 3641.	3.2	2
780	Serum antinuclear autoantibodies are associated with measures of oxidative stress and lifestyle factors: analysis of LIPIDOGRAM2015 and LIPIDOGEN2015 studies. Archives of Medical Science, 2023, 19, 1214-1227.	0.9	2
781	Secondary Stroke Prevention in Polish Adults: Results from the LIPIDOGRAM2015 Study. Journal of Clinical Medicine, 2021, 10, 4472.	2.6	2
782	The Effect of Graded Systemic Hypoxaemia on Hepatic Tissue Oxygenation. Advances in Experimental Medicine and Biology, 2003, 540, 317-323.	9.0	2
783	Carotid Artery Pathology in Inflammatory Diseases. American Journal of the Medical Sciences, 2022, 363, 209-217.	1.1	2
784	The burden of carotid-related strokes. Annals of Translational Medicine, 2022, 10, 159-159.	1.7	2
785	The Association between Coffee and Caffeine Consumption and Renal Function: Insight from Individual-Level Data, Mendelian Randomization, and Meta-Analysis. Archives of Medical Science, 2021, , .	0.9	2
786	Optimal management of asymptomatic carotid stenosis in 2021: the jury is still out. An international, multispecialty, expert review and position statement. International Angiology, 2022, 41, .	0.9	2
787	A Call to Encourage Participation in the Reviewing Process: The REFEREE Acrostic. International Journal of Lower Extremity Wounds, 2022, , 153473462211026.	1.2	2
788	Triacylglycerol lowering properties of the adenosine analog GR 79236 during 5 days of dosing large, old rats: A pilot study. Nutrition Research, 1996, 16, 1925-1932.	3.1	1
789	Editorial [PCI and Stable Coronary Heart Disease - COURAGE to Change Our Minds?]. Current Vascular Pharmacology, 2007, 5, 173-174.	1.5	1
790	Sodium-Lithium Countertransport Activity in Healthy, Dyslipidemic, and Hypertensive Individuals. Angiology, 2008, 59, 727-735.	1.8	1
791	Arteriovenous Fistula Leading to Severe Tortuosity and Aneurysm Formation. Journal of Cardiac Surgery, 2009, 24, 109-109.	0.8	1
792	Effects of l-Canavanine and ozone on vascular reactivity in septicemic rats. Journal of Physiology and Biochemistry, 2010, 66, 255-264.	3.1	1

#	ARTICLE	IF	CITATIONS
793	eComment: Endovascular repair of ruptured abdominal aortic aneurysms: identifying issues which may be difficult to achieve. <i>Interactive Cardiovascular and Thoracic Surgery</i> , 2010, 10, 619-619.	1.2	1
794	Raised liver enzymes in patients taking statins – Authors' reply. <i>Lancet</i> , The, 2011, 377, 1075-1076.	12.2	1
795	Letter by Paraskevas et al Regarding Article, “Guidelines for the Prevention of Stroke in Patients With Stroke or Transient Ischemic Attack: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association” <i>Stroke</i> , 2011, 42, e387.	5.0	1
796	Estimated Glomerular Filtration rate (eGFR): A Serum Creatinine-Based Test for the Detection of Chronic Kidney Disease and its Impact on Clinical Practice. <i>Oman Medical Journal</i> , 2012, 27, 260-260.	0.9	1
797	Regarding “Estimating the risk of solid organ malignancy in patients undergoing routine computed tomography scans after endovascular aneurysm repair” <i>Journal of Vascular Surgery</i> , 2012, 56, 1829.	1.1	1
798	Statins and Infrainguinal Vascular Bypass Procedures. <i>Current Vascular Pharmacology</i> , 2012, 11, 51-57.	1.5	1
799	Editorial: [Aliskiren/Amlodipine Single-Pill Combinations: More Evidence in Favour of Combination Formulations for the Treatment of Hypertension]. <i>Current Vascular Pharmacology</i> , 2012, 10, 745-747.	1.5	1
800	Alcohol consumption and the heart. <i>International Journal of Cardiology</i> , 2013, 168, 4319.	1.7	1
801	Editorial (Thematic Issues: Managing the Cardiovascular Risk Associated with the Metabolic) <i>Tj ETQq1 1 0.784314 1.59 /Overlock 10</i>	1.5	1
802	Drug Evaluation: The Combination of Fenofibrate and Simvastatin for the Treatment of Dyslipidemia: When and for Whom?. , 2015, , 179-190.		1
803	Critical Issues and Controversies in Carotid Artery Stenosis. <i>Angiology</i> , 2016, 67, 789-790.	1.8	1
804	C-reactive protein levels and aortic aneurysmal disease progression after endovascular repair: The jury is still out. <i>International Journal of Cardiology</i> , 2016, 203, 1141.	1.7	1
805	Response letter: Statins and non-alcoholic steatohepatitis. <i>Metabolism: Clinical and Experimental</i> , 2017, 66, e6.	3.7	1
806	Depression in cardiac and non-cardiac vascular diseases: Current evidence and future perspectives. <i>International Journal of Cardiology</i> , 2018, 271, 21-22.	1.7	1
807	Prehypertension, the Risk of Hypertension and Events. <i>Updates in Hypertension and Cardiovascular Protection</i> , 2019, , 37-55.	0.0	1
808	CETP inhibition in the REVEAL trial: could we aim higher?. <i>Archives of Medical Science</i> , 2020, 16, 1229-1230.	0.9	1
809	Unsuccessful treatment of cutaneous leishmaniasis by <i>Leishmania infantum</i> with topical paromomycin. <i>International Journal of Dermatology</i> , 2020, 59, e251-e252.	1.0	1
810	Adherence to statin treatment: an important issue in clinical practice. <i>Current Medical Research and Opinion</i> , 2016, 32, 1639-1640.	2.0	1

#	ARTICLE	IF	CITATIONS
811	Letter to Editor: Effects of Losartan vs. Enalapril on the Markers of Metabolic Syndrome. Oman Medical Journal, 2012, 27, 177-177.	0.9	1
812	Incidence of contrast-induced acute kidney injury in patients with acute mesenteric ischemia and identification of potential predictive factors. Vascular, 2022, 30, 1097-1106.	0.9	1
813	Statins and Fibrates: Should They Be Recommended?. , 2015, , 11-23.		1
814	Obstructive sleep apnea and cardiovascular disease: Is mean platelet volume one of the links?. Anatolian Journal of Cardiology, 2016, 16, 223.	0.8	1
815	The Heart Outcomes Prevention Evaluation (HOPE)-3 trial: where do we stand?. Current Opinion in Lipidology, 2017, 28, 88-89.	2.8	1
816	Perivascular adipose tissue in cardiovascular diseases. Anatolian Journal of Cardiology, 2019, 23, 58.	0.8	1
817	Relationship Between Anti-DFS70 Autoantibodies and Oxidative Stress. Biomarker Insights, 2022, 17, 117727192110667.	2.9	1
818	Statin use and renal function after aortic aneurysm repair procedures. Journal of Vascular Surgery, 2021, 74, 2121-2122.	1.1	1
819	Celebrating the 90th birthday of the scientist who discovered statins: Akira Endo. European Heart Journal, 2024, 45, 647-650.	2.4	1
820	Altered Cavernosal Endothelin-B-Receptor Binding Sites in the Rabbit Model of Partial Bladder Outlet Obstruction. Journal of Cardiovascular Pharmacology, 2000, 36, S260-S261.	1.9	0
821	The Treatment of Coronary Heart Disease: An Update Part 5: Selected Comments and Questions Compiled by. Current Medical Research and Opinion, 2001, 17, 41-42.	2.0	0
822	In vivo and in vitro response of corpus cavernosum to phosphodiesterase-5 inhibition in the hypercholesterolaemic rabbit. BJU International, 2005, 96, 1424-1424.	2.8	0
823	Editorial [Hot Topic: Biochemical and Clinical Relevance of Hyperuricaemia (Executive Editor: Dimitri) Tj ETQq1 1 0.784314 rgBT /Over 4115-4116.	1.9	0
824	¿Qué papel desempeña la diabetes mellitus en las tasas de reestenosis y permeabilidad tras la revascularización infrainginal? Revisión crítica. Annals of Vascular Surgery, 2008, 22, 525-536.	0.0	0
825	Le diabète joue-t-il un rôle dans les restenoses et les taux de perméabilité après revascularisation artérielle des membres inférieurs ? une étude géométrique critique. Annales De Chirurgie Vasculaire, 2008, 22, 521-532.	0.0	0
826	Multiple actions of high-density lipoprotein. Current Opinion in Internal Medicine, 2008, 7, 432-440.	0.7	0
827	Deterioro de la función renal en la arteriopatía periférica: un parámetro que no debe ser infravalorado. Annals of Vascular Surgery, 2009, 23, 759-769.	0.0	0
828	L'insuffisance rénale dans la maladie artérielle périphérique : Un paramètre important qui ne devrait pas être négligé. Annales De Chirurgie Vasculaire, 2009, 23, 749-759.	0.0	0

#	ARTICLE	IF	CITATIONS
829	Trials by Independent Expert Bodies. Archives of Internal Medicine, 2010, 170, 2042.	3.8	0
830	The role of ezetimibe in LDL cholesterol goal attainment in very high risk patients. Current Medical Research and Opinion, 2011, 27, 1961-1961.	2.0	0
831	Carotid artery stenting may be contraindicated in female patients with symptomatic carotid artery stenosis. Journal of Vascular Surgery, 2011, 54, 1870-1871.	1.1	0
832	Carotid Artery Stenosis and Heart Valve Surgery: A Complex Scenario. Angiology, 2011, 62, 597-600.	1.8	0
833	Fibrinogen, Hematocrit, and Platelets in Mild Kidney Dysfunction and the Role of Uric Acid: An Italian Male Population Study. Clinical and Applied Thrombosis/Hemostasis, 2012, 18, 113-114.	1.7	0
834	Carotid artery stenting: "Good news" or "bad news" for post-procedural cognitive function?. International Journal of Cardiology, 2012, 157, 156.	1.7	0
835	Heparin and platelet activation. Thrombosis Research, 2012, 130, 685.	1.7	0
836	Comment to "Atorvastatin improves disease activity of nonalcoholic steatohepatitis partly through its tumour necrosis factor- α -lowering property". Digestive and Liver Disease, 2013, 45, 82-83.	1.0	0
837	Omega-3 fatty acids for the treatment of nonalcoholic fatty liver disease in children and adolescents. Clinical Lipidology, 2013, 8, 509-512.	0.4	0
838	Platelet cholesterol: From man to seal. Platelets, 2013, 24, 253-254.	2.1	0
839	Editorial (Hot Topic: Achieving Current Goals in Prevention and Treatment of Vascular Disease: An) Tj ETQq1 1 0.784314 rgBT ₀ /Overlook	1.3	0
840	Reaching hypertriglyceridemia goals. Current Medical Research and Opinion, 2014, 30, 391-393.	2.0	0
841	The Effects of Anti-Diabetic Drugs on LDL Subclasses: Any Role for Colesevelam?. Cardiovascular Drugs and Therapy, 2014, 28, 205-207.	2.9	0
842	Implications of the timely diagnosis of lower extremity peripheral arterial disease. International Journal of Cardiology, 2014, 173, 551.	1.7	0
843	Do We Need Guideline-Driven Specific Lipid Goals to Achieve Regression of Coronary Atherosclerosis and Maximize Therapy Benefits?. American Journal of Cardiology, 2015, 115, 280.	1.6	0
844	Editorial: Your VISION Will Become Clear Only When You Look Into Your Heart. Current Vascular Pharmacology, 2016, 14, 319-320.	1.5	0
845	Statins, renal function and homocysteine. Pharmacological Reports, 2016, 68, 1093.	3.4	0
846	Coronary Artery Bypass Grafting Combined with Open Versus Endovascular Abdominal Aortic Aneurysm Repair. Annals of Vascular Surgery, 2016, 33, 263-264.	1.0	0

#	ARTICLE	IF	CITATIONS
847	Cardiovascular Risk Factors and Peripheral Arterial Disease. , 2018, , 189-200.		0
848	Carotid Artery Stenting Has a Role in the Management of Asymptomatic Carotid Stenosis, but This Is Currently Small. Angiology, 2018, 69, 640-641.	1.8	0
849	Statins and substantially increased <scp>ALT</scp> values at baseline. Cardiovascular Therapeutics, 2018, 36, e12444.	2.6	0
850	Vascular surgical procedures in patients with familial hypercholesterolaemia: is it too late?. Current Medical Research and Opinion, 2020, 36, 1255-1255.	2.0	0
851	Cardiovascular Risk Factors and Peripheral Arterial Disease. , 2006, , 133-140.		0
852	Cardiovascular Risk Factors and Peripheral Arterial Disease. , 2010, , 165-172.		0
853	Epidemiology and Pathophysiology of Carotid Artery Disease. , 2011, , 1-7.		0
854	Cardiovascular effects of laparoscopic sleeve gastrectomy. Turk Kardiyoloji Dernegi Arsivi, 2019, 47, 159-161.	0.5	0
855	Comment on "Long-term Prognosis After Elective Abdominal Aortic Aneurysm Repair is Poor in Women and Men: The Challenges Remain". Annals of Surgery, 2021, 274, e857-e858.	4.5	0
856	Endocrine Disease as a Cause of Cardiovascular Disease: Current Perspectives. Current Pharmaceutical Design, 2020, 26, 5547-5550.	1.9	0
857	Peripheral Arterial Disease and Emerging Biochemical Vascular Risk Factors. , 2007, , 111-116.		0
858	Lipids and Peripheral Arterial Disease. , 2007, , 35-40.		0
859	Re: biomedical publications profile and trends in gulf cooperation council countries. , 2012, 12, 378-9.		0
860	C-reactive protein-albumin ratio and erectile dysfunction. Andrologia, 2022, , e14386.	2.2	0
861	Optimal Management of Asymptomatic Carotid Stenosis: Counterbalancing the Benefits with the Potential Risks. Journal of Stroke, 2022, 24, 163-165.	3.3	0
862	Clinical benefit of statin treatment on patients with non-alcoholic fatty liver disease or steatohepatitis. Clinics and Research in Hepatology and Gastroenterology, 2022, 46, 101842.	1.6	0
863	The role of nutraceuticals in heart failure muscle wasting as a result of inflammatory activity. The International Lipid Expert Panel (ILEP) Position Paper.. Archives of Medical Science, 0, , .	0.9	0